var title_f22_57_23440="Cesarean delivery breech PI";
var content_f22_57_23440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Cesarean delivery for a breech pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a c-section, the doctor makes an incision in the belly and then the uterus. The baby comes out through that incision, rather than through the vagina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23440=[""].join("\n");
var outline_f22_57_23440=null;
var title_f22_57_23441="Grade IV liver trauma";
var content_f22_57_23441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Grade IV liver trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan shows a hypodense region greater than 10 cm in diameter within the dome of the liver (arrows in A and B) consistent with a grade IV liver injury. A moderate size subcapsular hematoma (arrowheads in A and B) is noted posteriorly.",
"    <div class=\"footnotes\">",
"     CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23441=[""].join("\n");
var outline_f22_57_23441=null;
var title_f22_57_23442="Mallory body alcoholic steatohepatitis - very high power";
var content_f22_57_23442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mallory body in patient with alcoholic steatohepatitis (very high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A ring of hyaline droplets next to a nucleus is typical of Mallory alcoholic hyaline. These droplets are made up of keratin filaments that are bound to other proteins, such as the heat shock protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23442=[""].join("\n");
var outline_f22_57_23442=null;
var title_f22_57_23443="Eczema herpeticum";
var content_f22_57_23443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eczema herpeticum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23443=[""].join("\n");
var outline_f22_57_23443=null;
var title_f22_57_23444="C1 inhibitor concentrate (human): Drug information";
var content_f22_57_23444=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   C1 inhibitor concentrate (human): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/54/38755?source=see_link\">",
"    see \"C1 inhibitor concentrate (human): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/49/11028?source=see_link\">",
"    see \"C1 inhibitor concentrate (human): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6759053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Berinert&reg;;",
"     </li>",
"     <li>",
"      Cinryze&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13261898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Berinert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6761341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6764794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Routine prophylaxis against  hereditary angioedema (HAE) attacks (Cinryze&reg;)",
"     </b>",
"     : I.V.: 1000 units every 3-4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of abdominal, facial, or laryngeal HAE attacks (Berinert&reg;):",
"     </b>",
"     I.V.: 20 units/kg",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6764793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/49/11028?source=see_link\">",
"      see \"C1 inhibitor concentrate (human): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: Dosage not established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6764795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6764799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Berinert&reg;: 500 units [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cinryze&reg;: 500 units [contains sucrose 21 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6764774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11368727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assistance with procurement and reimbursement of Cinryze&reg; is available for healthcare providers and patients through the CINRYZE",
"     <i>",
"      Solutions",
"     </i>",
"     &reg; program (telephone: 1-877-945-1000) or at file://www.cinryze.com/Cinryze_Solutions/Default.aspx",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6764796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Berinert&reg;: Administer intravenously at ~4 mL/minute; use within 8 hours of reconstitution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinryze&reg;: Administer intravenously at 1 mL/minute (over 10 minutes); use within 3 hours of reconstitution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Self-administration: Following patient training and instructions on self-administration, patient may self-administer treatment (Berinert&reg;) or prophylaxis (Cinryze&reg;) therapy.  Epinephrine should be available during self-administration in the event of an acute, severe hypersensitivity reaction. Patient suffering from an acute laryngeal HAE attack and self-administering should be informed to seek immediate medical attention following treatment (potential for airway obstruction to occur).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6764775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Berinert&reg;: Treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinryze&reg;: Routine prophylaxis against angioedema attacks in patients with HAE",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6764807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Erythema, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain/discomfort, abnormal taste, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Vulvovaginal fungal infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Infusion-related reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis,upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome, hereditary angioedema attack symptoms exacerbated, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic reaction, chills, hypersensitivity reaction, injection site erythema, injection site pain, shock, stroke, thrombotic events, transient ischemic attack",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6764780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of anaphylactic or life-threatening hypersensitivity reactions to human C1 inhibitor or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6764781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity: Severe hypersensitivity reactions (eg, urticaria, hives, wheezing, hypotension, anaphylaxis) may occur rarely during or after administration. Signs/symptoms of hypersensitivity reactions may be similar to the attacks associated with hereditary angioedema, therefore, consideration should be given to treatment methods. In the event of acute hypersensitivity reactions to C1 inhibitor therapy, treatment should be discontinued and epinephrine should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thrombotic events: Consider potential risk of thrombosis with use; thrombotic events have been reported with use at recommended doses and when used off-label at doses higher than recommended. Closely monitor patients with preexisting risks for thrombotic events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special Populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Safety and efficacy have been established in adolescents and adults. Only a small number of children were included in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-administration: Due to the potential for airway obstruction, patients suffering from an acute laryngeal HAE attack and self-administering should be informed to immediately seek medical attention following treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6764785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6764777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6764778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Information related to use during pregnancy is limited. Pregnancy may increase the incidence of attacks in patients with HAE.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6764779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Berinert Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (1): $2344.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cinryze Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (1): $2792.54",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6764789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C1 inhibitor, one of the serine proteinase inhibitors found in human blood, plays a role in regulating the complement and intrinsic coagulation (contact system) pathway, and is also involved in the fibrinolytic and kinin pathways. C1 inhibitor therapy in patients with C1 inhibitor deficiency, such as HAE, is believed to suppress contact system activation via inactivation of plasma kallikrein and factor XIIa, thus preventing bradykinin production. Unregulated bradykinin production is thought to contribute to the increased vascular permeability and angioedema observed in HAE.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6764790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Cinryze&reg;: Increased plasma C1 inhibitor levels observed ~1 hour or less",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of symptom relief: Berinert&reg;: Median: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to complete resolution of HAE symptoms: Berinert&reg;: Median: 8.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : Berinert&reg;:  ~19 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Adults (following a single dose):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Berinert&reg;: 22 hours (range: 17-24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cinryze&reg;: 56 hours (range: 11-108 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Cinryze&reg;: ~4 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cicardi M and Zingale L, &ldquo;How Do We Treat Patients With Hereditary Angioedema,&rdquo;",
"      <i>",
"       Transfus Apher Sci",
"      </i>",
"      , 2003, 29(3):221-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23444/abstract-text/14572813/pubmed\" id=\"14572813\" target=\"_blank\">",
"        14572813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farkas H, Jakab L, Temesszentandrasi G, et al, &ldquo;Hereditary Angioedema: A Decade of Human C1-inhibitor Concentrate Therapy,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2007, 120(4):941-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23444/abstract-text/17761272/pubmed\" id=\"17761272\" target=\"_blank\">",
"        17761272",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frank MM and Jiang H, &ldquo;New Therapies for Hereditary Angioedema: Disease Outlook Changes Dramatically,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2008, 121(1):272-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23444/abstract-text/18206518/pubmed\" id=\"18206518\" target=\"_blank\">",
"        18206518",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hermans C, &ldquo;Successful Management With C1-Inhibitor Concentrate of Hereditary Angioedema Attacks During Two Successive Pregnancies: A Case Report,&rdquo;",
"      <i>",
"       Arch Gynecol Obstet",
"      </i>",
"      , 2007, 276(3):271-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23444/abstract-text/17653743/pubmed\" id=\"17653743\" target=\"_blank\">",
"        17653743",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8998 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23444=[""].join("\n");
var outline_f22_57_23444=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6759053\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13261898\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6761341\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764794\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764793\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764795\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682372\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682373\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764799\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764774\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11368727\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764796\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764775\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764807\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764780\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764781\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298919\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764785\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764777\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764778\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764779\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321852\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764789\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6764790\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8998\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8998|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/54/38755?source=related_link\">",
"      C1 inhibitor concentrate (human): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/49/11028?source=related_link\">",
"      C1 inhibitor concentrate (human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_57_23445="Alprostadil: Pediatric drug information";
var content_f22_57_23445=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alprostadil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"    see \"Alprostadil: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/15/23796?source=see_link\">",
"    see \"Alprostadil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Caverject Impulse&reg;;",
"     </li>",
"     <li>",
"      Caverject&reg;;",
"     </li>",
"     <li>",
"      Edex&reg;;",
"     </li>",
"     <li>",
"      Muse&reg;;",
"     </li>",
"     <li>",
"      Prostin VR Pediatric&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alprostadil Injection USP;",
"     </li>",
"     <li>",
"      Caverject&reg;;",
"     </li>",
"     <li>",
"      Muse&reg; Pellet;",
"     </li>",
"     <li>",
"      Prostin&reg; VR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Prostaglandin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12706651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous I.V. infusion: 0.05-0.1 mcg/kg/minute; once therapeutic response is achieved, reduce rate to lowest effective dosage; with unsatisfactory response, increase rate gradually; maintenance: 0.01-0.4 mcg/kg/minute; higher doses may be required in patients receiving ECMO support (Stone, 2006); apnea may be less likely to occur at doses &lt;0.015 mcg/kg/minute (Browning Carmo, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     PGE",
"     <sub>",
"      1",
"     </sub>",
"     is usually given at an infusion rate of 0.1 mcg/kg/minute, but it is often possible to reduce the dosage to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     or even",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      10",
"     </sub>",
"     without losing the therapeutic effect.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"      see \"Alprostadil: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous I.V. infusion: Infants: 0.05-0.1 mcg/kg/minute; once therapeutic response is achieved, reduce rate to lowest effective dosage; with unsatisfactory response, increase rate gradually; maintenance: 0.01-0.4 mcg/kg/minute.",
"     <b>",
"      Note:",
"     </b>",
"     PGE",
"     <sub>",
"      1",
"     </sub>",
"     is usually given at an infusion rate of 0.1 mcg/kg/minute, but it is often possible to reduce the dosage to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     or even",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      10",
"     </sub>",
"     without losing the therapeutic effect.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caverject Impulse&reg;: 10 mcg, 20 mcg [contains benzyl alcohol (in diluent), lactose 45.4 mg; cartridge; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caverject&reg;: 20 mcg, 40 mcg [contains benzyl alcohol (in diluent), lactose 172 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edex&reg;: 10 mcg, 20 mcg, 40 mcg [contains lactose 51.06 mg; cartridge; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 500 mcg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prostin VR Pediatric&reg;: 500 mcg/mL (1 mL) [contains dehydrated ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pellet, urethral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Muse&reg;: 125 mcg (1s, 6s); 250 mcg (1s, 6s); 500 mcg (1s, 6s); 1000 mcg (1s, 6s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution for injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V. continuous infusion into a large vein or alternatively through an umbilical artery catheter placed at the ductal opening; maximum concentration listed (per package insert) for I.V. infusion: 20 mcg/mL; has also been administered via continuous infusion into the right pulmonary artery for investigational treatment of pulmonary hypertension in infants and children with congenital heart defects with left-to-right shunts; rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by standard concentration (mcg/mL)",
"    </p>",
"   </div>",
"   <div class=\"block uicn drugH1Div\" id=\"F14471276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10 mcg/mL",
"     <b>",
"      or",
"     </b>",
"     20 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Compatible in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, and saline solutions; refrigerate ampuls at 2&deg;C to 8&deg;C. Avoid direct contact of undiluted alprostadil with the plastic walls of volumetric infusion chambers because the drug will interact with the plastic and create a hazy solution; discard solution and volumetric chamber if this occurs.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary maintenance of patency of ductus arteriosus in neonates with ductal-dependent congenital heart disease until surgery can be performed. These defects include cyanotic (eg, pulmonary atresia, pulmonary stenosis, tricuspid atresia, Fallot's tetralogy, transposition of the great vessels) and acyanotic (eg, interruption of aortic arch, coarctation of aorta, hypoplastic left ventricle) heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Investigationally used for the treatment of pulmonary hypertension in infants and children with congenital heart defects with left-to-right shunts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adult males: Diagnosis and treatment of erectile dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F132214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Alprostadil may be confused with alPRAZolam",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F132212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intraurethral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Penile pain, testicular pain, urethral bleeding (minor), urethral burning, vaginal itching (female partner)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Leg pain, perineal pain, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intracavernosal injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Penile edema, penile fibrosis, penile pain, penile rash, penis disorder, prolonged erection (&gt;4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site hematoma and/or bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Balanitis, injection site hemorrhage, priapism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intravenous:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrest, edema, flushing, hyper-/hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Disseminated intravascular coagulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, cough, flu syndrome, nasal congestion, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Localized pain in structures other than the injection site, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anemia, anuria, bleeding, bradypnea, bronchial wheezing, cerebral bleeding, CHF, gastric regurgitation, hematuria, hyperbilirubinemia, hyperemia, hyperextension of neck, hyperirritability, hyperkalemia, hypoglycemia, hypothermia, jitteriness, lethargy, peritonitis, second-degree heart block, shock, stiffness, supraventricular tachycardia, thrombocytopenia, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alprostadil or any component; respiratory distress syndrome or persistent fetal circulation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use cautiously in neonates with bleeding tendencies. If hypotension or pyrexia occurs, the infusion rate should be reduced until symptoms subside; severe hypotension, apnea, or bradycardia requires drug discontinuation with cautious reinstitution at a lower dose. Flushing of arm or face during infusion may indicate misplacement of intra-arterial catheter and drug infusing into subclavian or carotid artery; repositioning of catheter necessary. Tissue necrosis may occur with extravasation of concentrated solutions (due to high osmolality). Cortical proliferation (cortical hyperostosis) of long bones has been associated with long-term infusions of alprostadil; incidence and severity are related to duration of therapy and cumulative dose;",
"     <b>",
"      Note:",
"     </b>",
"     Cortical hyperostosis may present with clinical symptoms that mimic cellulitis or osteomyelitis (eg, symptomatic bone tenderness, soft tissue swelling).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apnea occurs in 10% to 12% of neonates with congenital heart defects (especially in those weighing &lt;2 kg at birth) and usually appears during the first hour of drug infusion",
"     <b>",
"      [U.S. Boxed Warnings]",
"     </b>",
"     . May cause gastric outlet obstruction in neonates secondary to antral hyperplasia; occurrence is related to duration of therapy and cumulative dose. Infuse alprostadil at lowest effective dose and for shortest period of time; weigh risks of long-term effects versus benefits.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of Alprostadil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X/C (Muse&reg;) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F132153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alprostadil is embryotoxic in animal studies. It is not indicated for use in women. The manufacturer of Muse&reg; recommends a condom barrier when being used during sexual intercourse with a pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Arterial pressure, respiratory rate, heart rate, temperature, pO",
"     <sub>",
"      2",
"     </sub>",
"     ; monitor for gastric obstruction in patients receiving PGE",
"     <sub>",
"      1",
"     </sub>",
"     for longer than 120 hours; x-rays may be needed to assess cortical hyperostosis in patients receiving prolonged PGE",
"     <sub>",
"      1",
"     </sub>",
"     therapy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes vasodilation by means of direct effect on vascular and ductus arteriosus smooth muscle",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1050914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acyanotic congenital heart disease: Usual: 1.5-3 hours; range: 15 minutes to 11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyanotic congenital heart disease: Usual: &sim;30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Ductus arteriosus will begin to close within 1-2 hours after drug is stopped",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: &sim;70% to 80% metabolized by oxidation during a single pass through the lungs; metabolite (13,14 dihydro-PGE",
"     <sub>",
"      1",
"     </sub>",
"     ) is active and has been identified in neonates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 5-10 minutes; since the half-life is so short, the drug must be administered by continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Metabolites excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic response is indicated by an increase in systemic blood pressure and pH in those with restricted systemic blood flow and acidosis, or by an increase in oxygenation (pO",
"     <sub>",
"      2",
"     </sub>",
"     ) in those with restricted pulmonary blood flow. Most cases of bone changes occurred 4-6 weeks after starting alprostadil, but it has occurred as early as 9 days; cortical hyperostosis usually resolves over 6-12 months after stopping PGE",
"     <sub>",
"      1",
"     </sub>",
"     therapy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Other dosage forms of alprostadil [Caverject&reg; injection, Caverject&reg; Impulse&trade; injection, Edex&reg; injection, and Muse&reg; Pellet (urethral)] are indicated for the diagnosis and treatment of erectile dysfunction in adult males; see package inserts for further information for this use.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Browning Carmo KA, Barr P, West M, et al, \"Transporting Newborn Infants With Suspected Duct Dependent Congenital Heart Disease on Low-Dose Prostaglandin E1 Without Routine Mechanical Ventilation,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2007, 92(2):F117-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23445/abstract-text/16905574/pubmed\" id=\"16905574\" target=\"_blank\">",
"        16905574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practices (ISMP), \"Standard Concentrations of Neonatal Drug Infusions,\"",
"      <i>",
"       ISMP",
"      </i>",
"      , 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman MB and El-Chaar GM, &ldquo;Bone and Tissue Changes Following Prostaglandin Therapy in Neonates,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(3):269-74, 277.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23445/abstract-text/8833563/pubmed\" id=\"8833563\" target=\"_blank\">",
"        8833563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis AB, Freed MD, Heymann MA, et al, &ldquo;Side Effects of Therapy With Prostaglandin E",
"      <sub>",
"       1",
"      </sub>",
"      in Infants With Critical Congenital Heart Disease,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1981, 64(5):893-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23445/abstract-text/7285304/pubmed\" id=\"7285304\" target=\"_blank\">",
"        7285304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peled N, Dagan O, Babyn P, et al, &ldquo;Gastric-Outlet Obstruction Induced by Prostaglandin Therapy in Neonates,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(8):505-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23445/abstract-text/1635565/pubmed\" id=\"1635565\" target=\"_blank\">",
"        1635565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23445/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stone DM, Frattarelli DA, Karthikeyan S, et al, \"Altered Prostaglandin E1 Dosage During Extracorporeal Membrane Oxygenation in a Newborn With Ductal-Dependent Congenital Heart Disease,\"",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 2006, 27(3):360-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23445/abstract-text/16565906/pubmed\" id=\"16565906\" target=\"_blank\">",
"        16565906",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weesner KM, &ldquo;Hemodynamic Effects of Prostaglandin E",
"      <sub>",
"       1",
"      </sub>",
"      in Patients With Congenital Heart Disease and Pulmonary Hypertension,&rdquo;",
"      <i>",
"       Cathet Cardiovasc Diagn",
"      </i>",
"      , 1991, 24(1):10-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23445/abstract-text/1913785/pubmed\" id=\"1913785\" target=\"_blank\">",
"        1913785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woo K, Emery J, and Peabody J, &ldquo;Cortical Hyperostosis: A Complication of Prolonged Prostaglandin Infusion in Infants Awaiting Cardiac Transplantation,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1994, 93(3):417-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/57/23445/abstract-text/8115200 /pubmed\" id=\"8115200 \" target=\"_blank\">",
"        8115200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13353 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-90A40F4040-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23445=[""].join("\n");
var outline_f22_57_23445=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708622\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132167\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132168\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050909\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706651\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050903\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132144\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132129\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050912\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471276\">",
"      Usual Infusion Concentrations: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471275\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050905\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050911\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132214\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132212\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050916\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050902\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050901\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298715\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132138\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132140\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132153\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050908\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050900\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050914\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050915\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050917\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13353\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13353|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=related_link\">",
"      Alprostadil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/15/23796?source=related_link\">",
"      Alprostadil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_57_23446="Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule";
var content_f22_57_23446=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/57/23446/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23446/contributors\">",
"     Shiyu Song, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/57/23446/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23446/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23446/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23446/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/57/23446/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23446/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/57/23446/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with locoregionally advanced, stage III or IV, head and neck squamous cell carcinoma are usually managed with a combined modality approach that includes surgery, radiation therapy (RT),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy. Traditionally, these tumors were managed with a combination of surgery and RT. More recently, definitive RT plus chemotherapy is being used for patients who desire organ preservation, for those who have surgically unresectable disease, and for those who are medically inoperable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=see_link\">",
"     \"Overview of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues regarding the optimal dose and schedule for patients receiving definitive RT are reviewed here. The principles of RT as applied to patients with head and neck cancer are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493366588\">",
"    <span class=\"h1\">",
"     INTEGRATION OF CHEMOTHERAPY WITH RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have not completely defined the optimal way to integrate radiation therapy (RT) and chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approaches include:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Induction chemoradiotherapy &ndash; the administration of a course of chemotherapy prior to definitive radiation therapy (RT)",
"     </li>",
"     <li>",
"      Concurrent chemoradiotherapy &ndash; the administration of chemotherapy at the same time as RT",
"     </li>",
"     <li>",
"      Sequential chemoradiotherapy &ndash; the administration of induction chemotherapy followed by the concurrent administration of chemotherapy with RT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general approach depends in part upon the primary site, and details are discussed in the relevant topics. In brief:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laryngeal cancers - Combined chemotherapy and radiation has become the treatment of choice for locoregionally advanced laryngeal tumors, based upon data from randomized trials conducted in patients with unresectable disease or in whom organ preservation is an important consideration. This approach produces locoregional control and survival rates that are similar to those with surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT without chemotherapy for patients with resectable cancer who choose larynx preservation therapy with RT and chemotherapy rather than surgery. Concurrent chemoradiotherapy is preferred over induction chemotherapy followed by RT because of decreased toxicity and the shorter time period in which treatment can be delivered. &nbsp;Laryngectomy-free survival and overall survival rates appear to be similar or better. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypopharyngeal tumors - Concurrent chemoradiotherapy is considered a standard approach for patients with hypopharyngeal tumors. In contrast to laryngeal cancer, concurrent chemoradiotherapy has never been directly compared to induction chemotherapy followed by RT, an approach that is less toxic to the oral mucosa than concurrent chemoradiotherapy, and which has been compared to surgery alone [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/1\">",
"       1",
"      </a>",
"      ]. As a result, some consider induction chemotherapy followed by RT alone to represent an acceptable treatment option. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oropharyngeal tumors - Concurrent chemoradiotherapy has become the treatment of choice for oropharyngeal tumors (tonsil, base of tongue) as well, particularly in view of the adverse functional consequences of surgery for T3 or T4 cancers involving these sites. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15224?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493366803\">",
"    <span class=\"h1\">",
"     DOSE AND SCHEDULE OF RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probability of tumor control correlates with both the dose of radiation and the volume of the cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/2\">",
"     2",
"    </a>",
"    ]. Radiation cell kill is an exponential function of dosage; as a result, the necessary dosage of radiation is roughly proportional to the number of cells in the tumor (tumor volume). Control of microscopic disease in head and neck cancer usually requires approximately 50 Gy of radiation, while large (T3 and T4) tumors require doses in the range of 70 Gy to achieve tumor control.",
"   </p>",
"   <p>",
"    Many different treatment schedules have been used. In the United States, conventional RT for definitive treatment of head and neck cancer is one daily 1.8 to 2.0 Gy fraction, five days per week, to a total dose of approximately 70 Gy over seven weeks. Regions of the neck presumed to contain subclinical disease are electively treated to 50 Gy in 25 fractions, while nodal regions adjacent to gross disease may receive 60 Gy in 30 fractions. These schedules were developed to allow the regeneration of normal tissues but not tumor cells during treatment.",
"   </p>",
"   <p>",
"    Initially treatment is given to the entire clinical target volume and concludes with an additional boost to areas of gross disease. The boost treatment can be delivered using external beam RT, although interstitial or intracavitary brachytherapy is an option in selected cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link&amp;anchor=H3#H3\">",
"     \"General principles of radiation therapy for head and neck cancer\", section on 'External beam radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although RT is typically given on a schedule of five treatments per week in the United States, there is increasing evidence that outcomes may be improved with alternative fractionation schedules. Alternative regimens are divided into two types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperfractionation exploits the differential radiation sensitivity of tumors and normal tissues, by using smaller doses of radiation in each fraction, given on a more frequent schedule. (See",
"      <a class=\"local\" href=\"#H99325300\">",
"       'Hyperfractionation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Accelerated fractionation attempts to reduce tumor repopulation as a major cause of radiotherapy failure by decreasing the total time over which radiation is administered. (See",
"      <a class=\"local\" href=\"#H1493367204\">",
"       'Accelerated fractionation RT'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99325300\">",
"    <span class=\"h1\">",
"     HYPERFRACTIONATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term toxicity to normal tissues depends in part upon the size of each treatment fraction as well as the total radiation dose. Decreasing the size of each radiation fraction should permit higher total doses without increasing late morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperfractionation administers multiple daily treatments with smaller than conventional fraction sizes given over approximately the same treatment duration. Typical hyperfractionation schedules use 1.1 to 1.2 Gy per fraction, two fractions per day, to total doses of 74 to 80 Gy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493366898\">",
"    <span class=\"h2\">",
"     Clinical trial results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple randomized trials have compared hyperfractionation with conventional once daily fractionation. These trials did not include the administration of concurrent chemotherapy.",
"   </p>",
"   <p>",
"    The results with this approach are illustrated by largest of the trials (RTOG 9003), in which 1113 patients with stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    cancer of the head and neck were randomly assigned to one of four schedules [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard (2",
"      <span class=\"nowrap\">",
"       Gy/fraction",
"      </span>",
"      per day, five days per week, to 70 Gy)",
"     </li>",
"     <li>",
"      Hyperfractionation (1.2",
"      <span class=\"nowrap\">",
"       Gy/fraction,",
"      </span>",
"      twice daily, five days per week, to 81.6 Gy)",
"     </li>",
"     <li>",
"      Accelerated fractionation with a treatment break (twice daily fractions of 1.6 Gy, five days per week, to 67.2 Gy in 42 fractions over 6 weeks, with a two week rest after 38.4 Gy)",
"     </li>",
"     <li>",
"      Accelerated fractionation (1.8 Gy per fraction per day, five days per week), without a treatment break, but with a concurrent boost field as a second daily treatment for the last 12 treatment days (total dose 72 Gy in 42 fractions over 6 weeks)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With median follow-up of 23 months, locoregional control was significantly better for those patients treated with hyperfractionation or accelerated fractionation with a concurrent boost as compared to standard fractionation (two-year locoregional control 54 versus 46 percent). There was also a trend toward improved disease-free survival with hyperfractionation (38 versus 32 percent, respectively, p=0.067) and accelerated fractionation with a concurrent boost (39 versus 32 percent, p=0.054). The difference in overall survival was not statistically significant for any group, although a trend was seen for hyperfractionation (55 versus 46 percent, respectively, p=0.13). Acute side effects were more frequent with these altered fractionation regimens than with conventional fractionation.",
"   </p>",
"   <p>",
"    Similarly, a meta-analysis that combined the results of four trials assessing hyperfractionation (including RTOG 9003) found that there was a significant decrease in the risk of locoregional failure with hyperfractionation compared with conventional fractionation (hazard ratio [HR] 0.76, 48.5 versus 57.9 percent at five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/4\">",
"     4",
"    </a>",
"    ]. Similarly, there was an improvement in overall survival (hazard ratio [HR] 0.78, 36.7 versus 28.5 percent at five years). Notably, in subset analysis, there was a significant age-related benefit, with youngest patients benefitting the most and those over 70 not benefitting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493366929\">",
"    <span class=\"h2\">",
"     Optimal hyperfractionation schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data comparing different hyperfractionation schedules. The most extensive information comes from a trial (RTOG 8313) in which 479 patients with inoperable head and neck cancer were randomly assigned to different hyperfractionation doses, ranging from 67.2 to 81.6 Gy in twice daily 1.2 Gy fractions, with intertreatment intervals of four to eight hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/5\">",
"     5",
"    </a>",
"    ]. The majority of patients in this trial were treated for stage III or IV disease.",
"   </p>",
"   <p>",
"    Local control at two years was higher for hyperfractionated doses of 72 to 81.6 Gy as compared to 67.2 Gy (43 to 45 percent versus 25 percent), but there was no difference in survival among the groups. There was no apparent dose response relationship for late effects over the range of 67.2 to 81.6 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/6\">",
"     6",
"    </a>",
"    ]. However, there was a difference when the interinterval duration was considered. Estimates of late toxicity were significantly higher for intervals of 4.5 hours or less (5.5, 9.8, and 15.4 percent at one, two and three years, respectively) versus 1.7 percent for all three periods with intervals longer than 4.5 hour.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493366991\">",
"    <span class=\"h2\">",
"     Hyperfractionated RT plus chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of concurrent chemotherapy results in improved efficacy compared with hyperfractionated RT given without chemotherapy. This is illustrated by a trial in which 116 patients with head and neck cancer were randomly assigned to hyperfractionated RT either alone or with 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/7\">",
"     7",
"    </a>",
"    ]. Chemotherapy consisted of five days of cisplatin (12",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    as a daily bolus) and 5-FU (600",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day as continuous infusion), during week one and week six of irradiation. The RT alone group received 1.25 Gy twice daily for a total of 75 Gy, while the chemoradiotherapy group received 1.25 Gy twice daily, for a total of 70 Gy.",
"   </p>",
"   <p>",
"    At three years, chemoradiotherapy was associated with significantly higher rates of locoregional control (70 versus 44 percent), as well as a trend toward better relapse-free survival (61 versus 41 percent, p = 0.08) and overall survival (55 percent versus 34 percent, p = 0.07). Toxicity was similar in both groups.",
"   </p>",
"   <p>",
"    However, no trial has directly compared hyperfractionated RT with concurrent chemotherapy to conventional (once daily) fractionation with concurrent chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493367170\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In aggregate, these observations suggest a therapeutic advantage for hyperfractionated compared to conventional fractionation RT. However, these twice daily treatment schedules place greater time demands on the patient and the treatment facility, and may create problems with compliance. As a result, hyperfractionated regimens have not been widely adopted in the United States.",
"   </p>",
"   <p>",
"    Furthermore, there are no trials that directly address the question of whether hyperfractionation is superior to conventional RT when both are combined with concurrent chemotherapy, which is the current standard of care for most patients with locoregionally advanced. However, chemotherapy with accelerated fraction RT with a concomitant boost was studied in RTOG 0129 trial. (See",
"    <a class=\"local\" href=\"#H1493367204\">",
"     'Accelerated fractionation RT'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493367204\">",
"    <span class=\"h1\">",
"     ACCELERATED FRACTIONATION RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated fractionation attempts to reduce tumor repopulation as a major cause of radiotherapy failure, by decreasing the total time over which the radiation is administered. This can be accomplished either by using the same fraction size and administering treatments more frequently, or by changing other parameters (eg, fraction size, interval between treatments)",
"   </p>",
"   <p>",
"    The concept of accelerated RT has been evaluated in multiple randomized trials, which have used somewhat different dose fractionation schedules. A meta-analysis of these trials did not demonstrate a consistent survival advantage with accelerated RT regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of data from individual trials indicates that accelerated treatment using split courses of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/8-12\">",
"     8-12",
"    </a>",
"    ] or reduced total doses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/9,13,14\">",
"     9,13,14",
"    </a>",
"    ] do not improve locoregional tumor control or overall survival.",
"   </p>",
"   <p>",
"    Accelerated regimens that employ continuous rather than split course schedules without decreasing the total dose of radiation do appear to improve local control [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/3,15,16\">",
"     3,15,16",
"    </a>",
"    ]. The impact of this approach on overall survival is uncertain, with only one trial demonstrating a survival benefit.",
"   </p>",
"   <p>",
"    In that trial, 100 patients were randomly assigned to conventional RT (five days per week) or to continuous accelerated irradiation (seven days per week), both to a total dose of 66 to 72 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/16\">",
"     16",
"    </a>",
"    ]. The five-year local tumor control and overall survival rates were better with continuous accelerated irradiation (75 versus 33 percent and 62 versus 20 percent, respectively). However, confluent mucositis was significantly more common (94 versus 53 percent), more severe, and more prolonged with the continuous schedule compared with five day per week fractionation.",
"   </p>",
"   <p>",
"    Altered fractionation RT is considered by some to represent a standard approach for patients who are receiving RT alone for head and neck cancer. The results of RTOG 9003 led many oncologists to consider accelerated fractionation RT with a concurrent boost preferable to hyperfractionated RT in view of the cost and labor-intensiveness of twice daily RT. This approach may be particularly appropriate for patients with intermediate risk head and neck cancer (ie, T2 and favorable T3, N0-1 disease) who are receiving RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of chemotherapy to accelerated fractionation RT schedules is being studied. RTOG compared standard fractionation RT along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 22, 43 to accelerated fractionation RT with a concomitant boost and the same dose of cisplatin given concurrently on days 1 and 22. There was no difference in the three-year rate of survival (64.3 versus 70.3 percent, p=0.18) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23446/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493367318\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE NECK AFTER RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neck dissection is usually planned after completion of RT for patients who have an incomplete response or evidence of residual disease, because of the demonstrated improvement in locoregional control. Although controversial, many experts also recommend neck dissection for patients with initial N3 nodal disease, regardless of the response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493367428\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive radiation therapy (RT), usually administered with concurrent platinum-based chemotherapy, is the treatment of choice for patients with potentially resectable locoregionally advanced head and neck cancer who desire organ preservation, and for those who have surgically unresectable disease. Although direct comparative data are lacking, combined chemotherapy and RT appears to produce locoregional control and survival rates that are similar to surgery, while potentially preserving organ function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, conventional treatment regimens utilize a total dose of 70 Gy over seven weeks, given as a single fraction (2.0 Gy) once daily, five days per week, to disease containing areas. Nodal regions adjacent to gross disease may receive 60 Gy in 30 fractions, while regions of the neck presumed to contain subclinical disease are electively treated to 50 Gy in 25 fractions. (See",
"      <a class=\"local\" href=\"#H1493366803\">",
"       'Dose and schedule of RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Altered fractionation schedules have been extensive studied in an effort to achieve better disease control:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hyperfractionated regimens appear to improve both local control and overall survival when compared with once daily (conventional) fractionation RT when given without concurrent chemotherapy. However, there are no trials that directly address whether hyperfractionation is superior to conventional RT when both are combined with concurrent chemotherapy. Furthermore, twice daily treatment schedules place greater time demands on the patient and the treatment facility, and may create problems with compliance. As a result, hyperfractionated regimens have not been widely adopted in the United States. (See",
"      <a class=\"local\" href=\"#H99325300\">",
"       'Hyperfractionation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accelerated regimens using split courses of RT or reduced total doses do not improve locoregional tumor control or overall survival. Accelerated regimens that employ continuous schedules without decreasing the total dose of radiation do appear to improve local control but the impact on overall survival is uncertain. The available data suggest that accelerated RT regimens do not improve overall survival when given with concurrent chemotherapy. (See",
"      <a class=\"local\" href=\"#H1493367204\">",
"       'Accelerated fractionation RT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/1\">",
"      Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88:890.",
"     </a>",
"    </li>",
"    <li>",
"     Perez CA, Brady LW, Roti Roti JL. Overview. In: Principles and Practice of Radiation Oncology, Perez CA, Brady LW (Eds), Lippincott-Raven, Philadelphia 1998. p.7.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/3\">",
"      Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/4\">",
"      Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/5\">",
"      Cox JD, Pajak TF, Marcial VA, et al. ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313. Int J Radiat Oncol Biol Phys 1991; 20:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/6\">",
"      Fu KK, Pajak TF, Marcial VA, et al. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys 1995; 32:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/7\">",
"      Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/8\">",
"      Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/9\">",
"      Bourhis J, Lapeyre M, Tortochaux J, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006; 24:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/10\">",
"      Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997; 44:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/11\">",
"      Marcial VA, Pajak TF, Chang C, et al. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys 1987; 13:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/12\">",
"      Beck-Bornholdt HP, Dubben HH, Liertz-Petersen C, Willers H. Hyperfractionation: where do we stand? Radiother Oncol 1997; 43:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/13\">",
"      Dische S, Saunders M, Barrett A, et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/14\">",
"      Dobrowsky W, Naud&eacute; J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 2000; 57:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/15\">",
"      Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/16\">",
"      Skladowski K, Maciejewski B, Golen M, et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys 2006; 66:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/17\">",
"      Nguyen LN, Ang KK. Radiotherapy for cancer of the head and neck: altered fractionation regimens. Lancet Oncol 2002; 3:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23446/abstract/18\">",
"      Ang K, Zhang Q, Wheeler RH, et al. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome (abstract #5507). J Clin Oncol 2010.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3409 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-B86BBD9DD2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23446=[""].join("\n");
var outline_f22_57_23446=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1493367428\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1493366588\">",
"      INTEGRATION OF CHEMOTHERAPY WITH RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1493366803\">",
"      DOSE AND SCHEDULE OF RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H99325300\">",
"      HYPERFRACTIONATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1493366898\">",
"      Clinical trial results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1493366929\">",
"      Optimal hyperfractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1493366991\">",
"      Hyperfractionated RT plus chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1493367170\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1493367204\">",
"      ACCELERATED FRACTIONATION RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1493367318\">",
"      MANAGEMENT OF THE NECK AFTER RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1493367428\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=related_link\">",
"      Overview of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15224?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_57_23447="Atrial sensing pacer tutorial";
var content_f22_57_23447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dual chamber atrial sensing pacemaker",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 161px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAChAScDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3W6TH2z/R7wYgB+afOPvcn5+R7c9+PUukx9s/0e8GIAfmnzj73J+fke3Pfj1yLrw3Z/6Zx4gH7gfe1q5OPvcn9/yPbnvxzyXXhuz/ANM48QD9wPva1cnH3uT+/wCR7c9+OeZV+39aeR7UXHTXt/7b/eE2Y8X69/o94MaVafenzj95d8n5+R7c9+PXYukx9s/0e8GIAfmnzj73J+fke3Pfj15M+H7Q+KdciK66FTS7VgTrFxuBL3XLHzssvAwOQOcAZOdW68N2f+mceIB+4H3tauTj73J/f8j2578c8xC9tv6v6FNxute3/tv97+vzTx2mPCHij9xeDGlTH5p84/dycn5+R7c9+PXYukx9s/0e8GIAfmnzj73J+fke3Pfj15Pxr4ftIfC3iSVF13cmlyuBJrFw6ghJOWUzEMvscjg8c86t14bs/wDTOPEA/cD72tXJx97k/v8Ake3PfjnkV+bbt/WwJx5Vr/Xu/wB7+vz17pMfbP8AR7wYgB+afOPvcn5+R7c9+PXH2Y8X69/o94MaVafenzj95d8n5+R7c9+PVbrw3Z/6Zx4gH7gfe1q5OPvcn9/yPbnvxzzlHw/aHxTrkRXXQqaXasCdYuNwJe65Y+dll4GByBzgDJyO91p/VvQIONt+3/tv97+vz6y6TH2z/R7wYgB+afOPvcn5+R7c9+PXH8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj1W68N2f+mceIB+4H3tauTj73J/f8j2578c85XjXw/aQ+FvEkqLru5NLlcCTWLh1BCScspmIZfY5HB455JX5Xp/X3BSceaOvb/23+9/X59ZdJj7Z/o94MQA/NPnH3uT8/I9ue/HqXSY+2f6PeDEAPzT5x97k/PyPbnvx65F14bs/wDTOPEA/cD72tXJx97k/v8Ake3PfjnkuvDdn/pnHiAfuB97Wrk4+9yf3/I9ue/HPNq/b+tPImLjpr2/9t/vCbMeL9e/0e8GNKtPvT5x+8u+T8/I9ue/HrsXSY+2f6PeDEAPzT5x97k/PyPbnvx68mfD9ofFOuRFddCppdqwJ1i43Al7rlj52WXgYHIHOAMnOrdeG7P/AEzjxAP3A+9rVycfe5P7/ke3PfjnmIXtt/V/QpuN1r2/9t/vf1+aeO0x4Q8UfuLwY0qY/NPnH7uTk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578evJ+NfD9pD4W8SSouu7k0uVwJNYuHUEJJyymYhl9jkcHjnnVuvDdn/pnHiAfuB97Wrk4+9yf3/I9ue/HPIr823b+tgTjyrX+vd/vf1+evdJj7Z/o94MQA/NPnH3uT8/I9ue/Hrj7MeL9e/wBHvBjSrT70+cfvLvk/PyPbnvx6rdeG7P8A0zjxAP3A+9rVycfe5P7/AJHtz34555HVLrwppfjHXLPVNbuLGVNOtVCXPiOSOQOWuCQ2Z9zDa0Z284DZAG7kd7rT+vuCEopfF2/9t/vf1+fot0mPtn+j3gxAD80+cfe5Pz8j2578euP47THhDxR+4vBjSpj80+cfu5OT8/I9ue/HrkX0nhOLSZNUk1u7j0y4jEUN2/iWXyXf94MB/tGG+63AJPytxWR41u/CcPhDVbpNcn2XmnTiyaTxJI6XDqrqQoM5EoDYBUbueCOeSSfK9P6+4Kco8y97t/7b/ePRrpMfbP8AR7wYgB+afOPvcn5+R7c9+PUukx9s/wBHvBiAH5p84+9yfn5Htz349eCuNb8An7Vt8Vj5oQFz4sc8/N1/0nkcjjn6c89D/YemXdrNc2sutzW81qskUqa5cOjKQxD5E5DKRyMZ/Xm1ft/X3ExlF297t+n94k2Y8X69/o94MaVafenzj95d8n5+R7c9+PXYukx9s/0e8GIAfmnzj73J+fke3Pfj15M+H7Q+KdciK66FTS7VgTrFxuBL3XLHzssvAwOQOcAZOdW68N2f+mceIB+4H3tauTj73J/f8j2578c8xC9tv6v6FNxute3/ALb/AHv6/NPHaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349di6TH2z/AEe8GIAfmnzj73J+fke3Pfj15Pxr4ftIfC3iSVF13cmlyuBJrFw6ghJOWUzEMvscjg8c86t14bs/9M48QD9wPva1cnH3uT+/5Htz3455Ffm27f1sCceVa/17v97+vz17pMfbP9HvBiAH5p84+9yfn5Htz349cfZjxfr3+j3gxpVp96fOP3l3yfn5Htz349VuvDdn/pnHiAfuB97Wrk4+9yf3/I9ue/HPOUfD9ofFOuRFddCppdqwJ1i43Al7rlj52WXgYHIHOAMnI73Wn9W9Ag4237f+2/3v6/PrLpMfbP8AR7wYgB+afOPvcn5+R7c9+PXH8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj1W68N2f+mceIB+4H3tauTj73J/f8j2578c85XjXw/aQ+FvEkqLru5NLlcCTWLh1BCScspmIZfY5HB455JX5Xp/X3BSceaOvb/23+9/X59ZdJj7Z/o94MQA/NPnH3uT8/I9ue/HqXSY+2f6PeDEAPzT5x97k/PyPbnvx65F14bs/9M48QD9wPva1cnH3uT+/5Htz3455Lrw3Z/6Zx4gH7gfe1q5OPvcn9/yPbnvxzzav2/rTyJi46a9v/bf7wmzHi/Xv9HvBjSrT70+cfvLvk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578evJnw/aHxTrkRXXQqaXasCdYuNwJe65Y+dll4GByBzgDJzq3Xhuz/ANM48QD9wPva1cnH3uT+/wCR7c9+OeYhe239X9Cm43Wvb/23+9/X5p47THhDxR+4vBjSpj80+cfu5OT8/I9ue/HrsXSY+2f6PeDEAPzT5x97k/PyPbnvx68n418P2kPhbxJKi67uTS5XAk1i4dQQknLKZiGX2ORweOedW68N2f8ApnHiAfuB97Wrk4+9yf3/ACPbnvxzyK/Nt2/rYE48q1/r3f739fnupH/pko+zX3+rTj7RyOW6nf0/+vRWQvhuz+2S/J4h/wBWnH9t3Oerd/P/AM80UNPt/X3HNOUb/F2/L/GaN0mPtn+j3gxAD80+cfe5Pz8j2578epdJj7Z/o94MQA/NPnH3uT8/I9ue/HrkXWp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HqXWp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/Hraf9f0jeN9Ne3X/AA/3hNmPF+vf6PeDGlWn3p84/eXfJ+fke3Pfj12LpMfbP9HvBiAH5p84+9yfn5Htz349eTOoXY8U6448N67uOl2oMZurcsgD3XzN/pGCpycDJPynIGRnVutTvR9s/wCKX18YgB+a7tjj73J/0jke3Pfj1iG39f5FO91r26/4f739fmnjtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HryfjXULt/C3iRH8N67Cp0uUGSS6tyqApJ8zYuCSvsATweOedW61O9H2z/il9fGIAfmu7Y4+9yf9I5Htz349RfF939bAr8q1/H/AA/3v6/PXukx9s/0e8GIAfmnzj73J+fke3Pfj1x9mPF+vf6PeDGlWn3p84/eXfJ+fke3Pfj1W61O9H2z/il9fGIAfmu7Y4+9yf8ASOR7c9+PXKOoXY8U6448N67uOl2oMZurcsgD3XzN/pGCpycDJPynIGRke6/r9Ahe2/br/h/vf1+fWXSY+2f6PeDEAPzT5x97k/PyPbnvx64/jtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578eq3Wp3o+2f8AFL6+MQA/Nd2xx97k/wCkcj2578euV411C7fwt4kR/DeuwqdLlBkkurcqgKSfM2Lgkr7AE8Hjnkn8L/r9ApX5o69uv+H+9/X59ZdJj7Z/o94MQA/NPnH3uT8/I9ue/HqXSY+2f6PeDEAPzT5x97k/PyPbnvx65F1qd6Ptn/FL6+MQA/Nd2xx97k/6RyPbnvx6l1qd6Ptn/FL6+MQA/Nd2xx97k/6RyPbnvx62n/X9ImN9Ne3X/D/eE2Y8X69/o94MaVafenzj95d8n5+R7c9+PXYukx9s/wBHvBiAH5p84+9yfn5Htz349eTOoXY8U6448N67uOl2oMZurcsgD3XzN/pGCpycDJPynIGRnVutTvR9s/4pfXxiAH5ru2OPvcn/AEjke3Pfj1iG39f5FO91r26/4f739fmnjtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578ervGmuWPhbQNX1jVor9LO1t0LbZN7bmYqoxv5yzKBngd8DJrJ8a6hdv4W8SI/hvXYVOlygySXVuVQFJPmbFwSV9gCeDxzzB8QNW8Sw+Ftcfw14Z1lNVS0VoWuJ4JQg3Nvbas7FyE3FVw2WAG05wRfF939bEybjTvf8f8P97+vzy5PiSLPUtAg8QaYtpa+JrbOm3NnqUt0GY7dnmK0cZVW80euD1ABJHEftN+Dptcn1DWrG2uzc6Lp9pJKjP5mbd5bkO2BuJ2lUbqAFEhPasnxTpHiHWrv4eeIV8JeJnvbOaF9WnvAGmll3qWKo0haKLdFKQGEca7sgKG59kurma48Q+IY7jwvrUsUuk20clvLcWzjbvuslwZ9rK2SMZP3WyBkZqWjiY0/wB9CUX/AF8Pdr9f8+ctvG1j478AabbQSBdU8RwnTp4Rc/6oqjtdsF8xmAESuU3BsF4tww/Nn9oO0gsvgz4gtrSzltraCCzjiiDgJEouUAAUMRtwMADpjtXIfBHwXrnge/8AFf8Aa3h/WbnyR5FjIk8MYWNhukcoZwh3hIM7S+DGVzlSK3/j/qV5dfD/AFnS08L+JknuoYpEk2rcRRrFMru0rRSuEG0HG70PuaehPvSpNve3f08/0MfRPF2maxY+Cfh/caLd3NtqWhRG+a+SWJdkdq7KYQxG4b4wwkHygL8uScr6/oWkHQ/DVrpJW7mNhpsNt5pfYG2IV3ld5wDjO3Jxz+Pnvg4rqOheHPtPg/xVHqvhnT4YxLcQR22HNtJDIFM0iloz1wndFz6HvrrU70fbP+KX18YgB+a7tjj73J/0jke3Pfj1Lr+v+GNaUXo2+3Vf3f7wmzHi/Xv9HvBjSrT70+cfvLvk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578evJnULseKdcceG9d3HS7UGM3VuWQB7r5m/0jBU5OBkn5TkDIzq3Wp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HrENv6/yNXe617df8P97+vzTx2mPCHij9xeDGlTH5p84/dycn5+R7c9+PXYukx9s/0e8GIAfmnzj73J+fke3Pfj15PxrqF2/hbxIj+G9dhU6XKDJJdW5VAUk+ZsXBJX2AJ4PHPOrdanej7Z/wAUvr4xAD813bHH3uT/AKRyPbnvx6i+L7v62BX5Vr+P+H+9/X5690mPtn+j3gxAD80+cfe5Pz8j2578euPsx4v17/R7wY0q0+9PnH7y75Pz8j2578eq3Wp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HrlHULseKdcceG9d3HS7UGM3VuWQB7r5m/0jBU5OBkn5TkDIyPdf1+gQvbft1/w/wB7+vz6y6TH2z/R7wYgB+afOPvcn5+R7c9+PXH8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj1W61O9H2z/il9fGIAfmu7Y4+9yf9I5Htz349crxrqF2/hbxIj+G9dhU6XKDJJdW5VAUk+ZsXBJX2AJ4PHPJP4X/X6BSvzR17df8AD/e/r8+sukx9s/0e8GIAfmnzj73J+fke3Pfj1LpMfbP9HvBiAH5p84+9yfn5Htz349ci61O9H2z/AIpfXxiAH5ru2OPvcn/SOR7c9+PUutTvR9s/4pfXxiAH5ru2OPvcn/SOR7c9+PW0/wCv6RMb6a9uv+H+8Jsx4v17/R7wY0q0+9PnH7y75Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HryZ1C7HinXHHhvXdx0u1BjN1blkAe6+Zv9IwVOTgZJ+U5AyM6t1qd6Ptn/FL6+MQA/Nd2xx97k/6RyPbnvx6xDb+v8ine617df8AD/e/r808dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj12LpMfbP9HvBiAH5p84+9yfn5Htz349eT8a6hdv4W8SI/hvXYVOlygySXVuVQFJPmbFwSV9gCeDxzzq3Wp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HqL4vu/rYFflWv4/4f739fnupH/pko+zX3+rTj7RyOW6nf0/+vRWQmpXn2yUf8It4h/1acfbLbPVu/2n/PNFD/r+rHNO99+3Xy/xGjdJj7Z/o94MQA/NPnH3uT8/I9ue/HqXSY+2f6PeDEAPzT5x97k/PyPbnvx6l0mPtn+j3gxAD80+cfe5Pz8j2578epdJj7Z/o94MQA/NPnH3uT8/I9ue/Hrol/X3eRrGW2vbr/h/vf1+ePsx4v17/R7wY0q0+9PnH7y75Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/Hrj7MeL9e/wBHvBjSrT70+cfvLvk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578esU1p/Xf0KctVr26+Uf739fnj+O0x4Q8UfuLwY0qY/NPnH7uTk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578euP47THhDxR+4vBjSpj80+cfu5OT8/I9ue/HrsXSY+2f6PeDEAPzT5x97k/PyPbnvx6iXvfd/WwKXurX8f8P97+vzLpMfbP9HvBiAH5p84+9yfn5Htz349cOR4ovGWtpIlxGzaVabVkuRn/AFl1/t8j2578c87l0mPtn+j3gxAD80+cfe5Pz8j2578evinxX8HX/iz4rXVtZ6ZG8I8MKr3WoBpFtWNy+HRgTiTAbaMjIDe9Nrb+v0M/auKVtb+fp/e/r8/a7pMfbP8AR7wYgB+afOPvcn5+R7c9+PXH8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj18n8XN4y0/xjDaaVH4pFrZPYwNIRLcQ3UGAJZGK5jUfeyCWOcnKjgO1hvEv9k+MV1YeKxrf2e+IjIP9mrbbZNnz/dI2Y28li2QQRmiUbxFTr2afp+nme3XSY+2f6PeDEAPzT5x97k/PyPbnvx6l0mPtn+j3gxAD80+cfe5Pz8j2578evgtrJ44bRL9I5/FnmSXNgrGe2mWW3Qswmw0g+ZSOTwyrjqAavaTD420/xFG883iq9tIdTv7Nobsko9mqSGGR2wM5bGHJ2noOOKpL+vuFCs3b5dfTzPT7mWG08UeIZ7pbi3hj0m0LSTXICoPMu+WJfGPbnvxzzuXChlumWC72/ZwQTPnH3uT8/I9ue/HPPzQF8XanD4vtbyx8TTC48NK8lveRzvIky3GI1LOBv+UzEbQFPzYX5Sa6e/m+IA8O63DJaa3DqcN/b+eIN7RppxRsC3PVznG7GWHzdOlTCNhLEXevl+nn5f119Z8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj12LpMfbP9HvBiAH5p84+9yfn5Htz349fANWXxlc6HDbXV94nGnmy1VrueS2eJzEsQaFJjKCdud6gsAWG7HPNdr8b38RQ/YD4cGupGEkNzBarNJ5vB275YizIBzgEbTznGORL3vuNPatQT/X/D5npV0mPtn+j3gxAD80+cfe5Pz8j2578evNDU9OPjPXoxcfvPsFrbbTeqSJQ92ShHmcnHO3k9eOefJtV1bxbcajrun2jeK49btrTSja2qP58UMjR5m+1yAbdpG484BO7jjAzta07xbP4716Wy0m/ku7fXEmtPtMTiNIPLugkjMOse4n5uQcEZ5oa1X9dCade6fy/OPmfR90mPtn+j3gxAD80+cfe5Pz8j2578euP47THhDxR+4vBjSpj80+cfu5OT8/I9ue/Hr41rV144n07SCn/CX2sJ0oi7la3meZb8O24yIgyYsfd42EZ716z4iFw/w41l76C9+1nQnaYu+whzC+4su/gZz8vOOePUmvdZVCrzSXy/TzOkukx9s/0e8GIAfmnzj73J+fke3Pfj1LpMfbP9HvBiAH5p84+9yfn5Htz349S6TH2z/R7wYgB+afOPvcn5+R7c9+PUukx9s/0e8GIAfmnzj73J+fke3Pfj1pL+vu8hxltr26/4f739fnj7MeL9e/0e8GNKtPvT5x+8u+T8/I9ue/HrsXSY+2f6PeDEAPzT5x97k/PyPbnvx64+zHi/Xv8AR7wY0q0+9PnH7y75Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HrFNaf139CnLVa9uvlH+9/X54/jtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/Hrj+O0x4Q8UfuLwY0qY/NPnH7uTk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578eol733f1sCl7q1/H/D/e/r8y6TH2z/R7wYgB+afOPvcn5+R7c9+PXH2Y8X69/o94MaVafenzj95d8n5+R7c9+PXYukx9s/0e8GIAfmnzj73J+fke3Pfj1x9mPF+vf6PeDGlWn3p84/eXfJ+fke3Pfj1GtY/109AhLTft184/3v6/PYukx9s/0e8GIAfmnzj73J+fke3Pfj1x/HaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349di6TH2z/R7wYgB+afOPvcn5+R7c9+PXH8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj1Jr3X/X6BSl70de3X/D/e/r89i6TH2z/R7wYgB+afOPvcn5+R7c9+PUukx9s/0e8GIAfmnzj73J+fke3Pfj1LpMfbP9HvBiAH5p84+9yfn5Htz349S6TH2z/R7wYgB+afOPvcn5+R7c9+PW0v6+7yJjLbXt1/w/3v6/PH2Y8X69/o94MaVafenzj95d8n5+R7c9+PXYukx9s/0e8GIAfmnzj73J+fke3Pfj1x9mPF+vf6PeDGlWn3p84/eXfJ+fke3Pfj12LpMfbP9HvBiAH5p84+9yfn5Htz349YprT+u/oU5arXt18o/wB7+vzx/HaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349di6TH2z/R7wYgB+afOPvcn5+R7c9+PXH8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj12LpMfbP9HvBiAH5p84+9yfn5Htz349RL3vu/rYFL3Vr+P+H+9/X5zJH/AKZKPs19/q04+0cjlup39P8A69FCR/6ZKPs19/q04+0cjlup39P/AK9FDX9f0jmnPXft18v8RhXXhuz/ANM48QD9wPva1cnH3uT+/wCR7c9+OeS68N2f+mceIB+4H3tauTj73J/f8j2578c8690mPtn+j3gxAD80+cfe5Pz8j2578epdJj7Z/o94MQA/NPnH3uT8/I9ue/HrSiu39aeR0xqy097t1/w/3v6/Pkz4ftD4p1yIrroVNLtWBOsXG4EvdcsfOyy8DA5A5wBk51brw3Z/6Zx4gH7gfe1q5OPvcn9/yPbnvxzymzHi/Xv9HvBjSrT70+cfvLvk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578esQirbf1f0KdSV173br/h/vf1+fJ+NfD9pD4W8SSouu7k0uVwJNYuHUEJJyymYhl9jkcHjnnVuvDdn/pnHiAfuB97Wrk4+9yf3/I9ue/HPKeO0x4Q8UfuLwY0qY/NPnH7uTk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578eoorm27f1sCqS5V734/4f739fnkXXhuz/wBM48QD9wPva1cnH3uT+/5Htz3455yj4ftD4p1yIrroVNLtWBOsXG4EvdcsfOyy8DA5A5wBk56y6TH2z/R7wYgB+afOPvcn5+R7c9+PXjrv7Jr/AIt8YaXbXGq28tnp9jDd+TMAyFvtEgUliQVKOp+XPUjjmiUbWaX9W9CqNS7SlOyduv8Ah/vHIeM/Fej6brX2LS/7YuI1xHdSPrd2wA+bKriYhjyOpxwRjk103iCxsb3wd4kvLa28SxxrpUkkbXWqXBVx5chDFGnO5fZhg88c1E3wm8PwifMWrt5cW8GSeLr83Jx247c8V0Hi2yjsfAev2sFveLDb6NJGgefJVVikALfPyMDp7Hj15acK3vOra3T+rHr42vl/JShg3JyW7b31jr8X9IsXXhuz/wBM48QD9wPva1cnH3uT+/5Htz3455Lrw3Z/6Zx4gH7gfe1q5OPvcn9/yPbnvxzzr3SY+2f6PeDEAPzT5x97k/PyPbnvx6l0mPtn+j3gxAD80+cfe5Pz8j2578evaort/WnkeJGrLT3u3X/D/e/r8+TPh+0PinXIiuuhU0u1YE6xcbgS91yx87LLwMDkDnAGTnVuvDdn/pnHiAfuB97Wrk4+9yf3/I9ue/HPKbMeL9e/0e8GNKtPvT5x+8u+T8/I9ue/HrsXSY+2f6PeDEAPzT5x97k/PyPbnvx6xCKtt/V/Qp1JXXvduv8Ah/vf1+fJ+NfD9pD4W8SSouu7k0uVwJNYuHUEJJyymYhl9jkcHjnmfVrDRbG6lt7y41y3lngHledrdyAx+f8AiM2D/u5J68et3x2mPCHij9xeDGlTH5p84/dycn5+R7c9+PXV1C2jmivY57S5eMwDKSShh/FywLnI9ueh49Vy+9ouxdKqvd527eT/AMPmzkBpnhZfE2s2VqdVj1qS2RrjGr3Akk2q2N7ed8+1SOMnAJ4qY+H7Q+KdciK66FTS7VgTrFxuBL3XLHzssvAwOQOcAZOfNZ/hp4utL2W6t4beOWL99mG4UbBk9M49DXaWniCXRdXuf+E3hmsNRvLew02Hy5jKs0zvd7CdrHAbB4PA2npkZ5qNWc5KNSFte3/APXzDBUMNCM8LiFNWV1za3vHW3Ns/nbzOruvDdn/pnHiAfuB97Wrk4+9yf3/I9ue/HPOV418P2kPhbxJKi67uTS5XAk1i4dQQknLKZiGX2ORweOeesukx9s/0e8GIAfmnzj73J+fke3Pfj1x/HaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349eqUVyvT+vuPFpVJc0fe7df8P97+vzW68N2f+mceIB+4H3tauTj73J/f8j2578c8l14bs/8ATOPEA/cD72tXJx97k/v+R7c9+Oede6TH2z/R7wYgB+afOPvcn5+R7c9+PUukx9s/0e8GIAfmnzj73J+fke3Pfj1tRXb+tPImNWWnvduv+H+9/X58mfD9ofFOuRFddCppdqwJ1i43Al7rlj52WXgYHIHOAMnOrdeG7P8A0zjxAP3A+9rVycfe5P7/AJHtz3455TZjxfr3+j3gxpVp96fOP3l3yfn5Htz349di6TH2z/R7wYgB+afOPvcn5+R7c9+PWIRVtv6v6FOpK697t1/w/wB7+vz5Pxr4ftIfC3iSVF13cmlyuBJrFw6ghJOWUzEMvscjg8c86t14bs/9M48QD9wPva1cnH3uT+/5Htz3455Tx2mPCHij9xeDGlTH5p84/dycn5+R7c9+PXYukx9s/wBHvBiAH5p84+9yfn5Htz349RRXNt2/rYFUlyr3vx/w/wB7+vzyLrw3Z/6Zx4gH7gfe1q5OPvcn9/yPbnvxzzlHw/aHxTrkRXXQqaXasCdYuNwJe65Y+dll4GByBzgDJz1l0mPtn+j3gxAD80+cfe5Pz8j2578evJ6hrem6d8SrnSLw3kWo6ppUP2OJnZvM8prpnJIYgAKQcE884FDirrT+regQqSt8Xbr/AIf739fnq3Xhuz/0zjxAP3A+9rVycfe5P7/ke3PfjnnK8a+H7SHwt4klRdd3JpcrgSaxcOoISTllMxDL7HI4PHPPWXSY+2f6PeDEAPzT5x97k/PyPbnvx64/jtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578epKK5Xp/X3BSqS5o+926/wCH+9/X5rdeG7P/AEzjxAP3A+9rVycfe5P7/ke3PfjnkuvDdn/pnHiAfuB97Wrk4+9yf3/I9ue/HPOvdJj7Z/o94MQA/NPnH3uT8/I9ue/HqXSY+2f6PeDEAPzT5x97k/PyPbnvx62ort/WnkTGrLT3u3X/AA/3v6/Pkz4ftD4p1yIrroVNLtWBOsXG4EvdcsfOyy8DA5A5wBk51brw3Z/6Zx4gH7gfe1q5OPvcn9/yPbnvxzymzHi/Xv8AR7wY0q0+9PnH7y75Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HrEIq239X9CnUlde926/4f739fnyfjXw/aQ+FvEkqLru5NLlcCTWLh1BCScspmIZfY5HB4551brw3Z/wCmceIB+4H3tauTj73J/f8AI9ue/HPKeO0x4Q8UfuLwY0qY/NPnH7uTk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578eoorm27f1sCqS5V734/4f739fnnL4bs/tkvyeIf8AVpx/bdznq3fz/wDPNFa6R/6ZKPs19/q04+0cjlup39P/AK9FDiu39fcc06sr/F26+X+IwrrU70fbP+KX18YgB+a7tjj73J/0jke3Pfj1LrU70fbP+KX18YgB+a7tjj73J/0jke3Pfj117pMfbP8AR7wYgB+afOPvcn5+R7c9+PUukx9s/wBHvBiAH5p84+9yfn5Htz349bS/r+kbxmtPl1/w/wB7+vz5M6hdjxTrjjw3ru46Xagxm6tyyAPdfM3+kYKnJwMk/KcgZGdW61O9H2z/AIpfXxiAH5ru2OPvcn/SOR7c9+PVNmPF+vf6PeDGlWn3p84/eXfJ+fke3Pfj12LpMfbP9HvBiAH5p84+9yfn5Htz349YgtP6/wAinNXXy6/4f739fnyfjXULt/C3iRH8N67Cp0uUGSS6tyqApJ8zYuCSvsATweOedW61O9H2z/il9fGIAfmu7Y4+9yf9I5Htz349U8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj12LpMfbP8AR7wYgB+afOPvcn5+R7c9+PUS977v62BTXKv8/wDD/e/r88i61O9H2z/il9fGIAfmu7Y4+9yf9I5Htz349eA8K31ynxU+KUi6DrLu0enboVuYN8OLZseYTPhs9Rgtx1x0r1a6TH2z/R7wYgB+afOPvcn5+R7c9+PXzrwgn/F3Pix+5uuI9M/5bfd/0VvvfNyPzq7f1/SMZTXND17+S/vf1+fXXWp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HrleNdQu38LeJEfw3rsKnS5QZJLq3KoCknzNi4JK+wBPB4556y6TH2z/R7wYgB+afOPvcn5+R7c9+PXkPjHrln4d8AeIrm+S6jM9kbSBGuAS80odVGDJ8w53EDJCq5x6zKLat/X5GkayhaT2Vuv+H+9/X51m+I+kXHie88PW1jqcusi2dvsy31s5BQuHViLggsMEmPJYAE7cZNdDdanej7Z/wAUvr4xAD813bHH3uT/AKRyPbnvx6+M658LW8N/Ba3ubbTFi8Y6FHFqz3kaQK4dZHkkV2JbeqISAAfmMSnHO0+36ZqEGtaJFqlnb36217YRXUQlm+ZUdSwLDeexHHPQ/jXL/X9IinWu+V76dX5f3jBOoXY8U6448N67uOl2oMZurcsgD3XzN/pGCpycDJPynIGRnVutTvR9s/4pfXxiAH5ru2OPvcn/AEjke3Pfj1TZjxfr3+j3gxpVp96fOP3l3yfn5Htz349di6TH2z/R7wYgB+afOPvcn5+R7c9+PWILT+v8jVzV18uv+H+9/X58n411C7fwt4kR/DeuwqdLlBkkurcqgKSfM2Lgkr7AE8HjnnVutTvR9s/4pfXxiAH5ru2OPvcn/SOR7c9+PVPHaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349di6TH2z/AEe8GIAfmnzj73J+fke3Pfj1Eve+7+tgU1yr/P8Aw/3v6/PIutTvR9s/4pfXxiAH5ru2OPvcn/SOR7c9+PXyX4z3lw/inQnfRtUtmXVtHIjuJ4XZiHvcAYlYZbJxk4G1s7cjd7jdJj7Z/o94MQA/NPnH3uT8/I9ue/Hr458bl2+L/D/7q4T/AInGif62Xf8A8tL7/aP+QemeXbWP9dPQlTTi/l184/3memXWp3o+2f8AFL6+MQA/Nd2xx97k/wCkcj2578euV411C7fwt4kR/DeuwqdLlBkkurcqgKSfM2Lgkr7AE8HjnnrLpMfbP9HvBiAH5p84+9yfn5Htz349cfx2mPCHij9xeDGlTH5p84/dycn5+R7c9+PVTXuv+v0KpTXNH5df8P8Ae/r8+X8X/EOXSdXk0Oy8IeJL3xBcWiTw2nnIUERkKGSWRJJAiA55Ixkc7Qc0eFPHt9r9x4ksb3wdrVjq2klYbm1S+jlEYZWKMWkePcGwxG0MMAEEhhWV8M5Y/FPjn4geLgsk9vFING090vmmEUMS5kIO4KY5G2SADdyW9csuuT2/hb4+Ry3Ed5Z2XifRzb5e7Gye9ib5WcGTtGFRfUvgAljVpdP6/I5oVJXUuje3lprvc6g6hdjxTrjjw3ru46Xagxm6tyyAPdfM3+kYKnJwMk/KcgZGdW61O9H2z/il9fGIAfmu7Y4+9yf9I5Htz349U2Y8X69/o94MaVafenzj95d8n5+R7c9+PXYukx9s/wBHvBiAH5p84+9yfn5Htz349YgtP6/yOlzV18uv+H+9/X58n411C7fwt4kR/DeuwqdLlBkkurcqgKSfM2Lgkr7AE8HjnnVutTvR9s/4pfXxiAH5ru2OPvcn/SOR7c9+PVPHaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349di6TH2z/AEe8GIAfmnzj73J+fke3Pfj1Eve+7+tgU1yr/P8Aw/3v6/PIutTvR9s/4pfXxiAH5ru2OPvcn/SOR7c9+PXyXxxeXB/aI8ITHRtUilXS7kC1lnhaVx5dx8wYSldvPQsD8p45GfcbpMfbP9HvBiAH5p84+9yfn5Htz349fHPHa4/aW8GDyrhf+JVcna8m5v8AVXPOdx49s+vFO2q/rp6Eqacfu6+cf7zPTLrU70fbP+KX18YgB+a7tjj73J/0jke3Pfj1yvGuoXb+FvEiP4b12FTpcoMkl1blUBST5mxcElfYAng8c89ZdJj7Z/o94MQA/NPnH3uT8/I9ue/Hrj+O0x4Q8UfuLwY0qY/NPnH7uTk/PyPbnvx6qa91/wBfoVSmuaPy6/4f739fn598U/GHiptYg8K+CNE1Gz1+7tftks15NHJ5FsjNluJHjwxBXLnjoBlwRueCvG1/4i0bUmu/DGqjVdOZ9P1Fba7iaGO5j3b9pecFl5BxyByMt1OJ8EbR9ct/Enj/AFK3ke/8QO5tyswY21rGzRrGWwpPMeD13CNCRmrOj2X9gfHfxbYWluUs9b0WPWHRfkaKRJDEckPhwxaR2JGSW6cEtdv6/pHPGo04t9fP0t9r+rnRnULseKdcceG9d3HS7UGM3VuWQB7r5m/0jBU5OBkn5TkDIzq3Wp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HqmzHi/Xv9HvBjSrT70+cfvLvk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578esQWn9f5HQ5q6+XX/D/e/r8+T8a6hdv4W8SI/hvXYVOlygySXVuVQFJPmbFwSV9gCeDxzzq3Wp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HqnjtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HqJe9939bAprlX+f+H+9/X55yalefbJR/wi3iH/AFacfbLbPVu/2n/PNFa6R/6ZKPs19/q04+0cjlup39P/AK9FDX9f0jmnUV/u6+X+Mhukx9s/0e8GIAfmnzj73J+fke3Pfj1LpMfbP9HvBiAH5p84+9yfn5Htz349ci68N2f+mceIB+4H3tauTj73J/f8j2578c8l14bs/wDTOPEA/cD72tXJx97k/v8Ake3Pfjnm1ft/WnkbxcdNe3/tv94TZjxfr3+j3gxpVp96fOP3l3yfn5Htz349di6TH2z/AEe8GIAfmnzj73J+fke3Pfj18oPw0k/4SPWLc+MPiCPK062lMh1hN7bnuBtc45QbMgDpuf1rSuPhbIPtWfGvxG+WEE7taQ/3vvccj2HvSglYzdSpdaduv+HzOm+JFxb2PgjxRPeCe3hGmSLvmuQAGZXVQcvzliAF5JJwBk86Gl6pp+vaQdU0d57rT7m1EkUyz5BHzj5vnzwQQVPIIIIBrx/XPhLqcekatdeMfFut+JLXTtPmuoLO5+RFnWN/LkcmZ9wX5iB1JPPGQ1vV/hj4i8O+Ib6T4bGGy8P3FsHuNMv9Tuo445jkGRBC4J+VB95m5LcYC4S3+7+thqctL7euv2f7x7JdJj7Z/o94MQA/NPnH3uT8/I9ue/Hr514QT/i7nxY/c3XEemf8tvu/6K33vm5H51x+vXXjLwfeabceN10xdHv7uLT5ns9d1JXi8wSbZC0kxXau1ic54XHGc1v+FdEtpPip8UoGXWAkMenbSuqTq4zbMT5jCXL+2S2BwMdKpX/r/hiXOLlDXr+i/vf1+fq10mPtn+j3gxAD80+cfe5Pz8j2578evh3j2K28b/EPxK6w3F1pXg7QbgMGlikSPUJFfBJLMzAKvQHKyQ9B/EkGia18RfEfiaFdT1XR/CWk3N1pVxb22q3E1zdsihcSmV2TyzljhQeCVwch67XWfAmgeGvBXiaDQdM1LT4F06acwxalMEL+W/zOvnYccAYIPAxjFTO/K/6/Qqm+ecddLr9OnN8zudStYrm31CC5s7iSCS22SRyyh1ZSHBDAuQykdue/HPPlnwkWfwrrHif4e6jHen+zla+0l2fG+xdickgKrbXcbjzlmcAYU16BdeG7P/TOPEA/cD72tXJx97k/v+R7c9+Oeef8X/C7w74gmluru11qLU7aGNrfUF1OSS4ttrs4KtJI4xkHscZJGCc1Sv8A1/wwPo4vX/hv7zN/Zjxfr3+j3gxpVp96fOP3l3yfn5Htz349di6TH2z/AEe8GIAfmnzj73J+fke3Pfj18oPw0k/4SPWLc+MPiCPK062lMh1hN7bnuBtc45QbMgDpuf1rSuPhbIPtWfGvxG+WEE7taQ/3vvccj2HvSglYTqVLrTt1/wAPmdb47THhDxR+4vBjSpj80+cfu5OT8/I9ue/HrFoHirQfFa6y3h28kvlsR5E5jnJCON/PLfOh7MMqcNjPNcL4v+GT23hrxBM/i/4gTrDp0sjRXOsI8cgCOdsgx8yHGCPTPrTfFPwft9OK3/w0juPD2q2yKJYzeSiG7gLZeOVlkLgfKCCp5wQRkqyiXvaeQRqTsr7ev+Hz/r8/WbpMfbP9HvBiAH5p84+9yfn5Htz349fHPjcu3xf4f/dXCf8AE40T/Wy7/wDlpff7R/yD0zzBe+AfifqX9oT3fioaJLFajyrbTby6uIpz85zK80pZB0Hy7uMnbn73Fazqg8SXWlfbrPUbHVbDxDpel6jE+pTTotwr3gk8t2lY4+6VOcqd4B5LMtbrT+rehSnFpq76fnH+8z6fukx9s/0e8GIAfmnzj73J+fke3Pfj18k+MPiXWNTl8QeE/BlndLNaWBm1vULiRtlnAY2fy15IZ5EPHXAJxzuZF+NEc2nnRtB8O3mv2Ws67dRwLJ/aN3O8VshYzSgCYr8oKZDfwlzx94ad58N/DvhDwT4lj0PTtUtnGlO0sg1CRTMyxyYeVVkCsOp27dvLYUA4JK6i3/X5Ci+acY300vr6f3jsPDvhyx8K+HV0XSbW+js7O12p5lwGYkl2Z3w2DuYk4AxknAA4rH+L3hWTxT4Q1G2sYr2LVbNY7/T5fP8AmjuIy5Ug+YANw3ICSdu4tjIFbF14bs/9M48QD9wPva1cnH3uT+/5Htz3455Lrw3Z/wCmceIB+4H3tauTj73J/f8AI9ue/HPNa/1/ww7QceW+mn/tv945T4YeK7fxtBe6zDHMZ30ezju0jn4hnWS6DgqZCQufmUNk7SCRzz6FdJj7Z/o94MQA/NPnH3uT8/I9ue/Hr5ff/CbwVf8Ai/Xje+HLiVvsMF2WkvpS3myPcb5GPm5YtsXPXkE45Obdx8Evh6v2rb4UmXZCGXN/N8p+bk/vunA9elKCViXOomlp06/4fP8Ar8+s8fKE8HeKWaG7RV0mYkvPwv7uTlvn5Htz0PHrwVp8adEutQuGutI12x8PXbraadrc4cW07/vAS7MQEXcpA5bgMWCYYBPF3wb8B2HhzX7q08LTQz22nSzxMb6VvLcI5DEGUgjIHHPTp69jqfgPQLnSLrSrjTtUfTFtUjW0k1ScxIq52DZ52No2jAHTbwBRb3tPL+tgi5uKu7ejvf4d9fT+t+mukx9s/wBHvBiAH5p84+9yfn5Htz349fHPHa4/aW8GDyrhf+JVcna8m5v9Vc853Hj2z68Vo3HwP8PS28sGrXfinVYLSxMFnHf6ijrZZGA8YXAGAgwvK8cqeK8n0Wy1NP2iodB8RX2s3kljJexQy3V+zXH2Y20kkOZUYHlSGIBH3iMckU2tVb+tBQqPafW3W/WPmfVV0mPtn+j3gxAD80+cfe5Pz8j2578evKeIdc0bXfB3i1tDv49RWHSpfMNrqCTiLMcuN+2Q8HBwD6Hiuf8AjfZRaH8NPE97aJrBl+yxQYudWuZECyy+UxZfOIbhzgHIyOQRkHlvEvwbuPD2hX9z4V1/UNFhttFUalbwxkpqMkaSFpJB5+FDDI2gMBluOTmZfC/6/QqNW1SKjrt19P739fn1P7PK5+C+knyrhv3FwcrLhR/pM/JG4ce2Ox455qfHK1l0LWNA8e2tnIyaG/kX6vteRrafdGWDeYCSpYhV5GZCTgA53/Bnw7t/C3hNdGnudZupLaB8zRX01qh3SSPnyknKgfNjAznBOOedvVPCem3dtqNtdRa7JBLamOSOTWbllKkOCGHncqR2578c81rf+v8AISScEr66ff7v979BLSWC78S6xc2i3E1tLo9lLFKlyHRlL3RD5DkMpHIxn9edRryzuLzVrS3eSS6tIU+0Qrdh3gLBmXzFDkgEcgHqM8c8+Uv8HtFh1/xHp2jXninRNLl0+3mlsrDUVWJ9/nowkDbi6ER9CSfmfsQBq33wT8IQSPPoVjrPh+9t08xLvTtRZZVBWRWBLu/ysDzgZ4x0JBUErCdSpdaLp1/w+Z2XjtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/Hr5trHgIaL4f8AE11N4g8a6pt0ibEOo6xvjU7HIZlQruHykYORgtkHIrsrrw3Z/wCmceIB+4H3tauTj73J/f8AI9ue/HPKS97Ty/rY1pyvBcz/AB/w/wB43Uj/ANMlH2a+/wBWnH2jkct1O/p/9eishfDdn9sl+TxD/q04/tu5z1bv5/8Anmik0+39fcYTlG/xdvy/xmjdJj7Z/o94MQA/NPnH3uT8/I9ue/HqXSY+2f6PeDEAPzT5x97k/PyPbnvx65F1qd6Ptn/FL6+MQA/Nd2xx97k/6RyPbnvx6l1qd6Ptn/FL6+MQA/Nd2xx97k/6RyPbnvx62n/X9I3jfTXt1/w/3hNmPF+vf6PeDGlWn3p84/eXfJ+fke3Pfj12LpMfbP8AR7wYgB+afOPvcn5+R7c9+PXkzqF2PFOuOPDeu7jpdqDGbq3LIA918zf6RgqcnAyT8pyBkZ1brU70fbP+KX18YgB+a7tjj73J/wBI5Htz349Yht/X+RTvda9uv+H+9/X5p47THhDxR+4vBjSpj80+cfu5OT8/I9ue/HrsXSY+2f6PeDEAPzT5x97k/PyPbnvx68n411C7fwt4kR/DeuwqdLlBkkurcqgKSfM2Lgkr7AE8HjnnVutTvR9s/wCKX18YgB+a7tjj73J/0jke3Pfj1F8X3f1sCvyrX8f8P97+vzofFPw8fE3gbxHpUdtfmaWyEkKi4UEyoxkjBLMRtLooPtnp1rzb9nzXm8Vaz461iQXk081npazyswQtMls6SMQGwVLoxA9Ow6V6xdanej7Z/wAUvr4xAD813bHH3uT/AKRyPbnvx6+L/AeH+xfEPxPt9N0LUntIr7yI7eC4iBtVR5wEkLzANgEDgv8AdPPTNXX9f8Mc7g3UjJP8fJf3vM7D4FFr/wAOeLNbS1u0sda1i81GyLSgN5LMVBcB+u5GBBz909QQT2/jtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578evnfwEvrmH4P6YkWhavdIsE5E0E8Cxn/SJ+cNMpx2wV6g8c5PYeNdQu38LeJEfw3rsKnS5QZJLq3KoCknzNi4JK+wBPB455VTZ/1+hth7+7r26/4f7x1l0mPtn+j3gxAD80+cfe5Pz8j2578epdJj7Z/o94MQA/NPnH3uT8/I9ue/HrkXWp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HqXWp3o+2f8AFL6+MQA/Nd2xx97k/wCkcj2578etJ/1/SCN9Ne3X/D/eE2Y8X69/o94MaVafenzj95d8n5+R7c9+PXYukx9s/wBHvBiAH5p84+9yfn5Htz349eTOoXY8U6448N67uOl2oMZurcsgD3XzN/pGCpycDJPynIGRnVutTvR9s/4pfXxiAH5ru2OPvcn/AEjke3Pfj1iG39f5FO91r26/4f739fmnjtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HryfjXULt/C3iRH8N67Cp0uUGSS6tyqApJ8zYuCSvsATweOedW61O9H2z/AIpfXxiAH5ru2OPvcn/SOR7c9+PUXxfd/WwK/Ktfx/w/3v6/PXukx9s/0e8GIAfmnzj73J+fke3Pfj1+Z/GFjBp3xT1y3s4JoIT4v0Kco8pfEksM8jk5Y8szE+3TjpX0Ddanej7Z/wAUvr4xAD813bHH3uT/AKRyPbnvx6+D/FLSLvVv2hPD8unaLNZXcVpb6jPb3VzbrNcrDM5ZlIlIdtiAAbt2IzwAM1af9f0jnqJtw16rr5L+8z0Lxqsl/wDHbwjaWtpd7tK0u91C6aSZTtilRoVYEuSfnABUdj0POO18dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj14G9vrkfHyeX+wdZEg8JMv2driAyAfas7yfP2lO2N2c/w966rxrqF2/hbxIj+G9dhU6XKDJJdW5VAUk+ZsXBJX2AJ4PHPMzfu/1/kaYZttO/Xv8A4f7x1l0mPtn+j3gxAD80+cfe5Pz8j2578epdJj7Z/o94MQA/NPnH3uT8/I9ue/HrkXWp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HqXWp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HrSf9f0io3017df8P8AeE2Y8X69/o94MaVafenzj95d8n5+R7c9+PXYukx9s/0e8GIAfmnzj73J+fke3Pfj15M6hdjxTrjjw3ru46Xagxm6tyyAPdfM3+kYKnJwMk/KcgZGdW61O9H2z/il9fGIAfmu7Y4+9yf9I5Htz349Yht/X+RTvda9uv8Ah/vf1+aeO0x4Q8UfuLwY0qY/NPnH7uTk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578evJ+NdQu38LeJEfw3rsKnS5QZJLq3KoCknzNi4JK+wBPB4551brU70fbP+KX18YgB+a7tjj73J/wBI5Htz349RfF939bAr8q1/H/D/AHv6/PXukx9s/wBHvBiAH5p84+9yfn5Htz349fE/GdjFbftSeF54bR4WudKmeXLAvI6w3K72OTn5Qg5PRcdMV6rdanej7Z/xS+vjEAPzXdscfe5P+kcj2578evhXx7S+T4ieH/FE+jana6Xon2Nr3znjmkjVriQq3ySOAp8tlGSPmwDjcM1ezX9dPQzcbx5m9rPf/D/eZ337Q0T3Wg6NpBa8trTV9ZsbC7/eBmaJjI2ASWwdyKR7r6Eg9t47THhDxR+4vBjSpj80+cfu5OT8/I9ue/Hr5t8Y9Q1DUvFHgjRLfw9qcE76kmqD7VdwlnS1VmdVAlZSdrk/My4K4Gdxx2vjXULt/C3iRH8N67Cp0uUGSS6tyqApJ8zYuCSvsATweOeVP4f6/wAiqK99O/br/h/vefmdZdJj7Z/o94MQA/NPnH3uT8/I9ue/HqXSY+2f6PeDEAPzT5x97k/PyPbnvx65F1qd6Ptn/FL6+MQA/Nd2xx97k/6RyPbnvx6l1qd6Ptn/ABS+vjEAPzXdscfe5P8ApHI9ue/HrSf9f0gjfTXt1/w/3hNmPF+vf6PeDGlWn3p84/eXfJ+fke3Pfj12LpMfbP8AR7wYgB+afOPvcn5+R7c9+PXkzqF2PFOuOPDeu7jpdqDGbq3LIA918zf6RgqcnAyT8pyBkZ1brU70fbP+KX18YgB+a7tjj73J/wBI5Htz349Yht/X+RTvda9uv+H+9/X5p47THhDxR+4vBjSpj80+cfu5OT8/I9ue/HrsXSY+2f6PeDEAPzT5x97k/PyPbnvx68n411C7fwt4kR/DeuwqdLlBkkurcqgKSfM2Lgkr7AE8HjnnVutTvR9s/wCKX18YgB+a7tjj73J/0jke3Pfj1F8X3f1sCvyrX8f8P97+vz3Uj/0yUfZr7/Vpx9o5HLdTv6f/AF6KyE1K8+2Sj/hFvEP+rTj7ZbZ6t3+0/wCeaKH/AF/Vjmne+/br5f4jRukx9s/0e8GIAfmnzj73J+fke3Pfj1LpMfbP9HvBiAH5p84+9yfn5Htz349S6TH2z/R7wYgB+afOPvcn5+R7c9+PUukx9s/0e8GIAfmnzj73J+fke3Pfj10S/r7vI1jLbXt1/wAP97+vzx9mPF+vf6PeDGlWn3p84/eXfJ+fke3Pfj12LpMfbP8AR7wYgB+afOPvcn5+R7c9+PXH2Y8X69/o94MaVafenzj95d8n5+R7c9+PXYukx9s/0e8GIAfmnzj73J+fke3Pfj1imtP67+hTlqte3Xyj/e/r88fx2mPCHij9xeDGlTH5p84/dycn5+R7c9+PXYukx9s/0e8GIAfmnzj73J+fke3Pfj1x/HaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349di6TH2z/R7wYgB+afOPvcn5+R7c9+PUS977v62BS91a/j/AIf739fmXSY+2f6PeDEAPzT5x97k/PyPbnvx6+SaVeWPhX4ofFn7RYXtsr6db6xFDGpXzoooW8+UHcFfMj+pyxb0bHrd0mPtn+j3gxAD80+cfe5Pz8j2578evh/xfvYtP+KGrwz296G1HwLe2sH70Nh186Uljv8Au7Y2455xx3qv6/rQ56smkpLp/kv739fn1/wL065074QaNDe2twkrWTXA2zDbslllkRiA3QoynHUc5Ga6nx2mPCHij9xeDGlTH5p84/dycn5+R7c9+PWj8O0/4tt4ePk3X/ICsznzuB+56kbvu+314q947THhDxR+4vBjSpj80+cfu5OT8/I9ue/Hqp/C/wCv0N6Ds4q/br/h/vGxdJj7Z/o94MQA/NPnH3uT8/I9ue/HqXSY+2f6PeDEAPzT5x97k/PyPbnvx6l0mPtn+j3gxAD80+cfe5Pz8j2578epdJj7Z/o94MQA/NPnH3uT8/I9ue/HrSX9fd5CjLbXt1/w/wB7+vzx9mPF+vf6PeDGlWn3p84/eXfJ+fke3Pfj12LpMfbP9HvBiAH5p84+9yfn5Htz349cfZjxfr3+j3gxpVp96fOP3l3yfn5Htz349di6TH2z/R7wYgB+afOPvcn5+R7c9+PWKa0/rv6FOWq17dfKP97+vzx/HaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349di6TH2z/R7wYgB+afOPvcn5+R7c9+PXH8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj12LpMfbP8AR7wYgB+afOPvcn5+R7c9+PUS977v62BS91a/j/h/vf1+ZdJj7Z/o94MQA/NPnH3uT8/I9ue/Hr4v8S5U079oTwbf3cN5FZCza0MrbpAs063KRKWBONzdieisegNe0XSY+2f6PeDEAPzT5x97k/PyPbnvx6+NfH6Oe1lm1uC2laPQptH1KaKe45dFnu0Cg5bktIv0AY+xb3j/AF0J5rRbb7dfOPmbfhK0hb4zfFS5azlNzFDp8aSlwXjVrYlgW3ZKkopI5+6PQV2XjtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578evF/DRpdU8bfFTWjbSxQPfx6asYuSzK1rG0bM+SMhsqQPmxyOwJ7Tx2mPCHij9xeDGlTH5p84/dycn5+R7c9+PVTXuv+v0Fhna2vX9V/e/r89i6TH2z/AEe8GIAfmnzj73J+fke3Pfj1LpMfbP8AR7wYgB+afOPvcn5+R7c9+PUukx9s/wBHvBiAH5p84+9yfn5Htz349S6TH2z/AEe8GIAfmnzj73J+fke3Pfj1tL+vu8hxltr26/4f739fnj7MeL9e/wBHvBjSrT70+cfvLvk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578euPsx4v17/R7wY0q0+9PnH7y75Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HrFNaf139CnLVa9uvlH+9/X54/jtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/Hrj+O0x4Q8UfuLwY0qY/NPnH7uTk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578eol733f1sCl7q1/H/AA/3v6/Mukx9s/0e8GIAfmnzj73J+fke3Pfj18n+PdpNceFvHSW1nfPIulaZIV3mQqq3c7MxAY/KFUnvgAnjrXrF0mPtn+j3gxAD80+cfe5Pz8j2578evH+MbCfUD46srO0vHubjw3HDEjXA5dvtgGSXxgkjr70SWq/rp6EN3pyV+nf/AA/3v6/Pl/E+o2uvfF/4dzaOl5cQrpV7qTEhyUtpoCsUrEn5VLDGCQc8EfMAfQPHaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349fGvg/rNjrvjfRZdP89/svgRLKdfOG6OWK5CNuAc4XgMFPJVlO3mvZfHaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349XP4WLDT5mnfqv/bfM2LpMfbP9HvBiAH5p84+9yfn5Htz349S6TH2z/R7wYgB+afOPvcn5+R7c9+PUukx9s/0e8GIAfmnzj73J+fke3Pfj1LpMfbP9HvBiAH5p84+9yfn5Htz349aS/r7vIqMtte3X/D/e/r88fZjxfr3+j3gxpVp96fOP3l3yfn5Htz349di6TH2z/R7wYgB+afOPvcn5+R7c9+PXH2Y8X69/o94MaVafenzj95d8n5+R7c9+PXYukx9s/wBHvBiAH5p84+9yfn5Htz349YprT+u/oU5arXt18o/3v6/PH8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj12LpMfbP8AR7wYgB+afOPvcn5+R7c9+PXH8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj12LpMfbP9HvBiAH5p84+9yfn5Htz349RL3vu/rYFL3Vr+P+H+9/X5zJH/pko+zX3+rTj7RyOW6nf0/+vRQkf+mSj7Nff6tOPtHI5bqd/T/69FDX9f0jmnPXft18v8RhXXhuz/0zjxAP3A+9rVycfe5P7/ke3PfjnkuvDdn/AKZx4gH7gfe1q5OPvcn9/wAj2578c8690mPtn+j3gxAD80+cfe5Pz8j2578epdJj7Z/o94MQA/NPnH3uT8/I9ue/HrSiu39aeR0xqy097t1/w/3v6/Pkz4ftD4p1yIrroVNLtWBOsXG4EvdcsfOyy8DA5A5wBk51brw3Z/6Zx4gH7gfe1q5OPvcn9/yPbnvxzymzHi/Xv9HvBjSrT70+cfvLvk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578esQirbf1f0KdSV173br/AIf739fnyfjXw/aQ+FvEkqLru5NLlcCTWLh1BCScspmIZfY5HB4551brw3Z/6Zx4gH7gfe1q5OPvcn9/yPbnvxzynjtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HqKK5tu39bAqkuVe9+P8Ah/vf1+eRdeG7P/TOPEA/cD72tXJx97k/v+R7c9+OefA/2ldL/sXWYtYsmvQIbRLBory7lnZhdJeKzeYZSwAERwnKnJyMZDfSd0mPtn+j3gxAD80+cfe5Pz8j2578evjv7QfhubxBpPiNbOw1S4vbK10y6ghhPnMzefdRtuUFiV2SOeOQVzwM5bSTWn9W9DKc5SpSV+nf/D/eOy8LeEFsPB+nWepRa3DfW+k28VwiaxOEjkWMhuFm27cg4C8ccCpPGvh+0h8LeJJUXXdyaXK4EmsXDqCEk5ZTMQy+xyODxzz1l0mPtn+j3gxAD80+cfe5Pz8j2578euP47THhDxR+4vBjSpj80+cfu5OT8/I9ue/HqTiuV6f19xrSqO8Vzduv+H+9/X5rdeG7P/TOPEA/cD72tXJx97k/v+R7c9+OeS68N2f+mceIB+4H3tauTj73J/f8j2578c8690mPtn+j3gxAD80+cfe5Pz8j2578epdJj7Z/o94MQA/NPnH3uT8/I9ue/HrSiu39aeRMastPe7df8P8Ae/r8+TPh+0PinXIiuuhU0u1YE6xcbgS91yx87LLwMDkDnAGTnVuvDdn/AKZx4gH7gfe1q5OPvcn9/wAj2578c8psx4v17/R7wY0q0+9PnH7y75Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HrEIq239X9CnUlde926/4f739fnyfjXw/aQ+FvEkqLru5NLlcCTWLh1BCScspmIZfY5HB4551brw3Z/6Zx4gH7gfe1q5OPvcn9/yPbnvxzynjtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HqKK5tu39bAqkuVe9+P+H+9/X55F14bs/9M48QD9wPva1cnH3uT+/5Htz345589+LHhSC+0PxzBE2rwm30S1vA09/LcD93LcyEMGmIYERYGc7SSwGevrN0mPtn+j3gxAD80+cfe5Pz8j2578evN6xpkWq6x4s065hv0gu9Dt4JGW4G5VdrxSeWIPB44PQ8eo46qy/q3oQ5ylBxvuu/+H+9/X5+X/s5W8fiPwj4p1S+GpC4udUnlcWmpXESKWjVjuHmgvyTy25jjkmvSPGvh+0h8LeJJUXXdyaXK4EmsXDqCEk5ZTMQy+xyODxzzlfAzTL3S/hLptnqmnahaXkUExkhm3RMmZ5yCyMQcEEHGPU4556nx2mPCHij9xeDGlTH5p84/dycn5+R7c9+PV1Iqz0/r7h4eo1yq/br/h8xbrw3Z/6Zx4gH7gfe1q5OPvcn9/yPbnvxzyXXhuz/ANM48QD9wPva1cnH3uT+/wCR7c9+Oede6TH2z/R7wYgB+afOPvcn5+R7c9+PUukx9s/0e8GIAfmnzj73J+fke3Pfj1pRXb+tPII1Zae926/4f739fnyZ8P2h8U65EV10Kml2rAnWLjcCXuuWPnZZeBgcgc4Ayc6t14bs/wDTOPEA/cD72tXJx97k/v8Ake3PfjnlNmPF+vf6PeDGlWn3p84/eXfJ+fke3Pfj12LpMfbP9HvBiAH5p84+9yfn5Htz349YhFW2/q/oU6krr3u3X/D/AHv6/Pk/Gvh+0h8LeJJUXXdyaXK4EmsXDqCEk5ZTMQy+xyODxzzq3Xhuz/0zjxAP3A+9rVycfe5P7/ke3PfjnlPHaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349di6TH2z/AEe8GIAfmnzj73J+fke3Pfj1FFc23b+tgVSXKve/H/D/AHv6/PIuvDdn/pnHiAfuB97Wrk4+9yf3/I9ue/HPOUfD9ofFOuRFddCppdqwJ1i43Al7rlj52WXgYHIHOAMnPWXSY+2f6PeDEAPzT5x97k/PyPbnvx64+zHi/Xv9HvBjSrT70+cfvLvk/PyPbnvx6jirrT+regQqSt8Xbr/h/vf1+fz5+yhpsOoWfjPzxqH7uO2wbW9ltwMif7wR13dO+cc+vPt/jXw/aQ+FvEkqLru5NLlcCTWLh1BCScspmIZfY5HB4555P4G6RY2M3xKksrGSAjXrq1CwybEjiiz5aFQwGF3t0B/lXoHjtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578ermtG7f19xlhJOCjG/Xv5rz/r81uvDdn/AKZx4gH7gfe1q5OPvcn9/wAj2578c8l14bs/9M48QD9wPva1cnH3uT+/5Htz345517pMfbP9HvBiAH5p84+9yfn5Htz349S6TH2z/R7wYgB+afOPvcn5+R7c9+PWlFdv608i41Zae926/wCH+9/X58mfD9ofFOuRFddCppdqwJ1i43Al7rlj52WXgYHIHOAMnOrdeG7P/TOPEA/cD72tXJx97k/v+R7c9+OeU2Y8X69/o94MaVafenzj95d8n5+R7c9+PXYukx9s/wBHvBiAH5p84+9yfn5Htz349YhFW2/q/oU6krr3u3X/AA/3v6/Pk/Gvh+0h8LeJJUXXdyaXK4EmsXDqCEk5ZTMQy+xyODxzzq3Xhuz/ANM48QD9wPva1cnH3uT+/wCR7c9+OeU8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj12LpMfbP9HvBiAH5p84+9yfn5Htz349RRXNt2/rYFUlyr3vx/wAP97+vzzl8N2f2yX5PEP8Aq04/tu5z1bv5/wDnmitdI/8ATJR9mvv9WnH2jkct1O/p/wDXoocV2/r7jmnVlf4u3Xy/xGFdanej7Z/xS+vjEAPzXdscfe5P+kcj2578epdanej7Z/xS+vjEAPzXdscfe5P+kcj2578euvdJj7Z/o94MQA/NPnH3uT8/I9ue/HqXSY+2f6PeDEAPzT5x97k/PyPbnvx62l/X9I3jNafLr/h/vf1+fJnULseKdcceG9d3HS7UGM3VuWQB7r5m/wBIwVOTgZJ+U5AyM6t1qd6Ptn/FL6+MQA/Nd2xx97k/6RyPbnvx6psx4v17/R7wY0q0+9PnH7y75Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HrEFp/X+RTmrr5df8P97+vz5PxrqF2/hbxIj+G9dhU6XKDJJdW5VAUk+ZsXBJX2AJ4PHPOrdanej7Z/xS+vjEAPzXdscfe5P+kcj2578eqeO0x4Q8UfuLwY0qY/NPnH7uTk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578eol733f1sCmuVf5/4f739fnkXWp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HrlHULseKdcceG9d3HS7UGM3VuWQB7r5m/0jBU5OBkn5TkDIz1l0mPtn+j3gxAD80+cfe5Pz8j2578euPsx4v17/R7wY0q0+9PnH7y75Pz8j2578eo1qv6/QITVvu6/4f739fmt1qd6Ptn/ABS+vjEAPzXdscfe5P8ApHI9ue/HrleNdQu38LeJEfw3rsKnS5QZJLq3KoCknzNi4JK+wBPB4556y6TH2z/R7wYgB+afOPvcn5+R7c9+PXH8dpjwh4o/cXgxpUx+afOP3cnJ+fke3Pfj1Jr3X/X6BSmuaPy6/wCH+9/X5rdanej7Z/xS+vjEAPzXdscfe5P+kcj2578epdanej7Z/wAUvr4xAD813bHH3uT/AKRyPbnvx6690mPtn+j3gxAD80+cfe5Pz8j2578epdJj7Z/o94MQA/NPnH3uT8/I9ue/HraX9f0iYzWny6/4f739fnyZ1C7HinXHHhvXdx0u1BjN1blkAe6+Zv8ASMFTk4GSflOQMjOrdanej7Z/xS+vjEAPzXdscfe5P+kcj2578eqbMeL9e/0e8GNKtPvT5x+8u+T8/I9ue/HrsXSY+2f6PeDEAPzT5x97k/PyPbnvx6xBaf1/kU5q6+XX/D/e/r8+T8a6hdv4W8SI/hvXYVOlygySXVuVQFJPmbFwSV9gCeDxzzq3Wp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HqnjtMeEPFH7i8GNKmPzT5x+7k5Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HqJe9939bAprlX+f+H+9/X55F1qd6Ptn/FL6+MQA/Nd2xx97k/6RyPbnvx65R1C7HinXHHhvXdx0u1BjN1blkAe6+Zv9IwVOTgZJ+U5AyM9ZdJj7Z/o94MQA/NPnH3uT8/I9ue/Hrj7MeL9e/0e8GNKtPvT5x+8u+T8/I9ue/HqNar+v0CE1b7uv+H+9/X5rdanej7Z/wAUvr4xAD813bHH3uT/AKRyPbnvx65XjXULt/C3iRH8N67Cp0uUGSS6tyqApJ8zYuCSvsATweOeesukx9s/0e8GIAfmnzj73J+fke3Pfj1x/HaY8IeKP3F4MaVMfmnzj93Jyfn5Htz349Sa91/1+gUprmj8uv8Ah/vf1+a3Wp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HqXWp3o+2f8AFL6+MQA/Nd2xx97k/wCkcj2578euvdJj7Z/o94MQA/NPnH3uT8/I9ue/HqXSY+2f6PeDEAPzT5x97k/PyPbnvx62l/X9ImM1p8uv+H+9/X58mdQux4p1xx4b13cdLtQYzdW5ZAHuvmb/AEjBU5OBkn5TkDIzq3Wp3o+2f8Uvr4xAD813bHH3uT/pHI9ue/HqmzHi/Xv9HvBjSrT70+cfvLvk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578esQWn9f5FOauvl1/w/3v6/Pk/GuoXb+FvEiP4b12FTpcoMkl1blUBST5mxcElfYAng8c86t1qd6Ptn/FL6+MQA/Nd2xx97k/6RyPbnvx6p47THhDxR+4vBjSpj80+cfu5OT8/I9ue/HrsXSY+2f6PeDEAPzT5x97k/PyPbnvx6iXvfd/WwKa5V/n/h/vf1+eRdanej7Z/xS+vjEAPzXdscfe5P+kcj2578euUdQux4p1xx4b13cdLtQYzdW5ZAHuvmb/SMFTk4GSflOQMjPWXSY+2f6PeDEAPzT5x97k/PyPbnvx64+zHi/Xv9HvBjSrT70+cfvLvk/PyPbnvx6jWq/r9AhNW+7r/h/vf1+a3Wp3o+2f8AFL6+MQA/Nd2xx97k/wCkcj2578euV411C7fwt4kR/DeuwqdLlBkkurcqgKSfM2Lgkr7AE8HjnnrLpMfbP9HvBiAH5p84+9yfn5Htz349cfx2mPCHij9xeDGlTH5p84/dycn5+R7c9+PUmvdf9foFKa5o/Lr/AIf739fmt1qd6Ptn/FL6+MQA/Nd2xx97k/6RyPbnvx6l1qd6Ptn/ABS+vjEAPzXdscfe5P8ApHI9ue/Hrr3SY+2f6PeDEAPzT5x97k/PyPbnvx6l0mPtn+j3gxAD80+cfe5Pz8j2578etpf1/SJjNafLr/h/vf1+fJnULseKdcceG9d3HS7UGM3VuWQB7r5m/wBIwVOTgZJ+U5AyM6t1qd6Ptn/FL6+MQA/Nd2xx97k/6RyPbnvx6psx4v17/R7wY0q0+9PnH7y75Pz8j2578euxdJj7Z/o94MQA/NPnH3uT8/I9ue/HrEFp/X+RTmrr5df8P97+vz5PxrqF2/hbxIj+G9dhU6XKDJJdW5VAUk+ZsXBJX2AJ4PHPOrdanej7Z/xS+vjEAPzXdscfe5P+kcj2578eqeO0x4Q8UfuLwY0qY/NPnH7uTk/PyPbnvx67F0mPtn+j3gxAD80+cfe5Pz8j2578eol733f1sCmuVf5/4f739fnnJqV59slH/CLeIf8AVpx9sts9W7/af880VrpH/pko+zX3+rTj7RyOW6nf0/8Ar0UNf1/SOadRX+7r5f4ye+/5iH/XqP8A2ei+/wCYh/16j/2eiitzKPT5f+2mQ/8AyN/iP/sD2f8A6MvK177/AJiH/XqP/Z6KKmG39dyuq+X/ALaZHj//AJFDxZ/2B5v/AEXLWvff8xD/AK9R/wCz0UUL4n8gj8Mf6/kC+/5iH/XqP/Z6yH/5G/xH/wBgez/9GXlFFEt1/XQKe33f+2Gvff8AMQ/69R/7PWR4/wD+RQ8Wf9geb/0XLRRRP4WFL4o/L/20177/AJiH/XqP/Z6L7/mIf9eo/wDZ6KKomPT5f+2mQ/8AyN/iP/sD2f8A6MvK177/AJiH/XqP/Z6KKmG39dyuq+X/ALaZHj//AJFDxZ/2B5v/AEXLWvff8xD/AK9R/wCz0UUL4n8gj8Mf6/kC+/5iH/XqP/Z6yH/5G/xH/wBgez/9GXlFFEt1/XQKe33f+2Gvff8AMQ/69R/7PWR4/wD+RQ8Wf9geb/0XLRRRP4WFL4o/L/20177/AJiH/XqP/Z6L7/mIf9eo/wDZ6KKomPT5f+2mQ/8AyN/iP/sD2f8A6MvK177/AJiH/XqP/Z6KKmG39dyuq+X/ALaZHj//AJFDxZ/2B5v/AEXLWvff8xD/AK9R/wCz0UUL4n8gj8Mf6/kC+/5iH/XqP/Z6yH/5G/xH/wBgez/9GXlFFEt1/XQKe33f+2Gvff8AMQ/69R/7PWR4/wD+RQ8Wf9geb/0XLRRRP4WFL4o/L/20177/AJiH/XqP/Z6L7/mIf9eo/wDZ6KKomPT5f+2mQ/8AyN/iP/sD2f8A6MvK177/AJiH/XqP/Z6KKmG39dyuq+X/ALaZHj//AJFDxZ/2B5v/AEXLWvff8xD/AK9R/wCz0UUL4n8gj8Mf6/kLKf8AIQm/65R/zeiiimziqb/Jfkf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a normal or intrinsic P wave which, after a preset PR interval, is followed by a pacemaker spike and a paced QRS complex that has a bizarre morphology resembling a left bundle branch block or a ventricular complex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23447=[""].join("\n");
var outline_f22_57_23447=null;
var title_f22_57_23448="Lamellar osmophilic inclusions";
var content_f22_57_23448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron micrograph showing lamellar osmophilic inclusions in a glomerular podocyte",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The foot processes are intact. (Original magnification X20,000).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha- galactosidase A activity and genetic mutations on clinical course. Medicine 2002; 81:122. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23448=[""].join("\n");
var outline_f22_57_23448=null;
var title_f22_57_23449="Major side effects of amiodarone";
var content_f22_57_23449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Major side effects of amiodarone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/57/23449/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23449/contributors\">",
"     Elsa-Grace Giardina, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23449/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/57/23449/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23449/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/57/23449/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23449/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/57/23449/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    has multiple effects on myocardial depolarization and repolarization that make it an extremely effective antiarrhythmic drug. Its primary effect is to block the potassium channels, but it can also block sodium and calcium channels and the beta and alpha adrenergic receptors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approved clinical use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    has been limited to refractory ventricular arrhythmias because of a relatively high incidence of side effects that can range in severity from mild to potentially lethal (",
"    <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/1\">",
"     1",
"    </a>",
"    ]. The use of lower doses (200 to 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may allow amiodarone to be given safely and effectively in atrial arrhythmias such as atrial fibrillation or flutter. However, as will be described below, even low doses of therapy are associated with significant adverse effects, particularly thyroid, pulmonary, neurologic, skin, ocular, and bradycardic events (",
"    <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2\">",
"     2",
"    </a>",
"    ]. Many of these effects are due to the tissue accumulation of amiodarone with long-term oral therapy and are not seen with short-term intravenous therapy.",
"   </p>",
"   <p>",
"    Guidelines for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    were published by the North American Society of Pacing and Electrophysiology (NASPE) in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/3\">",
"     3",
"    </a>",
"    ]. It was estimated that the prevalence of side effects was as high as 15 percent in the first year and as high as 50 percent with long-term therapy. On the other hand, the need to stop amiodarone because of serious adverse effects is thought to be about 20 percent. In a meta-analysis of trials of low-dose therapy, there was a significantly higher rate of drug discontinuation with amiodarone compared to placebo (22.9 versus 15.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    will be reviewed here. The clinical uses of amiodarone, including recommendations for its use in the treatment of various arrhythmias, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link&amp;anchor=H8#H8\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\", section on 'Amiodarone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTRAVENOUS AMIODARONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is primarily given for short-term management of serious ventricular arrhythmias. It has a different electrophysiologic and pharmacologic profile from oral amiodarone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of the adverse effects associated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    described below are due to tissue accumulation of the drug with long-term therapy and are not seen with short-term use of intravenous amiodarone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/4\">",
"     4",
"    </a>",
"    ]. A major problem noted with the intravenous preparation is hypotension, which occurs in as many as 26 percent of patients and has been attributed to the solvents used in the preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Hypotension does not appear to occur with a preparation of amiodarone that employs an aqueous base [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of the published literature and a report from the Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    Multicenter Investigators Group of patients with frequent life-threatening ventricular arrhythmias, proarrhythmia was noted in 2 to 3 percent of patients treated with intravenous amiodarone; it is usually manifest as torsades de pointes but ventricular fibrillation can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In the multicenter study in which six of 342 patients developed proarrhythmia, all had an exacerbating factor such as acute ischemia or an electrolyte imbalance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other cardiac side effects (bradycardia, asystole, heart failure, and shock), nausea, vomiting, and abnormal liver function tests occurred in 1 to 5 percent of patients each [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Acute respiratory distress syndrome is a rare complication. When given through peripheral intravenous lines, local phlebitis was most likely when the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    concentration exceeded 2",
"    <span class=\"nowrap\">",
"     mg/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PULMONARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary involvement is the toxic effect responsible for most deaths associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29767?source=see_link\">",
"     \"Amiodarone pulmonary toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary toxicity generally correlates more closely with the total cumulative dose than with serum drug levels [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/8\">",
"       8",
"      </a>",
"      ]. As a result, pulmonary toxicity usually occurs several months to as late as several years after the initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/8\">",
"       8",
"      </a>",
"      ]. However, there are anecdotal cases of severe pulmonary toxicity developing within two to three weeks of therapy with low cumulative doses [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Initial reports in which patients were usually treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      doses &ge;400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      noted a 5 to 15 percent incidence of pulmonary toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/1,10,11\">",
"       1,10,11",
"      </a>",
"      ]. However, the incidence is lower with lower maintenance doses [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2,8,11\">",
"       2,8,11",
"      </a>",
"      ]. This was best illustrated in a meta-analysis of four randomized trials of 1465 patients in whom low dose amiodarone (mean 150 to 330",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      given to patients with heart failure or post-myocardial infarction) was compared to placebo for a minimum of one year [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2\">",
"       2",
"      </a>",
"      ]. There was a nonsignificant trend toward an increased incidence of pulmonary toxicity with amiodarone (1.9 versus 0.7 percent, odds ratio [OR] 2.2, 95 percent confidence interval [CI] 0.9 to 5.3).",
"     </li>",
"     <li>",
"      There are several different types of pulmonary toxicity. Chronic interstitial pneumonitis is most common; other manifestations include organizing pneumonia, acute respiratory distress syndrome, and a solitary pulmonary mass. One characteristic finding in all patients exposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is the presence of numerous foamy macrophages in the air spaces (",
"      <a class=\"graphic graphic_picture graphicRef53653 \" href=\"UTD.htm?20/60/21441\">",
"       picture 1",
"      </a>",
"      ). These cells are filled with amiodarone-phospholipid complexes.",
"     </li>",
"     <li>",
"      A nonproductive cough and dyspnea are present in 50 of 75 percent of affected individuals at presentation. Pleuritic pain, weight loss, fever (33 to 50 percent of cases), and malaise can also occur. The physical examination often reveals bilateral inspiratory crackles, while clubbing is not seen.",
"     </li>",
"     <li>",
"      Serial lung function studies are not helpful for predicting pulmonary toxicity. Although the DLCO is often decreased in patients with pulmonary toxicity, there is usually no premonitory change in DLCO among asymptomatic patients in whom symptomatic disease subsequently develops. As a result, the DLCO is",
"      <strong>",
"       not",
"      </strong>",
"      useful as a predictive index [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. In one report, for example, most asymptomatic patients with a fall in DLCO of more than 20 percent did not develop pulmonary toxicity over the next year despite continued",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The diagnosis of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      pulmonary toxicity is one of exclusion. The differential diagnosis of pulmonary processes that can present similarly to amiodarone toxicity includes heart failure, infectious pneumonia, pulmonary embolism, and malignancy.",
"     </li>",
"     <li>",
"      Treatment of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      pulmonary toxicity consists primarily of stopping amiodarone. Corticosteroid therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      40 to 60 mg per day, with a taper over two to six months) can be life saving for severe cases and for patients with less severe disease in whom withdrawal of amiodarone is not desirable. Due to its accumulation in fatty tissues and long elimination half-life (25 to 100 days), pulmonary toxicity may initially progress despite drug discontinuation and may recur upon steroid withdrawal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Preexisting pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between preexisting lung disease and the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity has been reported in some series. However, it is possible that these patients merely have limited pulmonary reserve and thus become symptomatic earlier in their course than other individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29767?source=see_link&amp;anchor=H13#H13\">",
"     \"Amiodarone pulmonary toxicity\", section on 'Preexisting lung disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THYROID DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid dysfunction (including both hypothyroidism and hyperthyroidism) is a common complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy. Although initial reports using higher doses noted hyperthyroidism or hypothyroidism in up to 20 percent of patients, the risk is lower (about 3 to 4 percent) when lower doses are used (",
"    <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2\">",
"     2",
"    </a>",
"    ]. Underlying thyroid status and iodine intake appear to influence the incidence and type of thyroid dysfunction seen with amiodarone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=see_link\">",
"     \"Amiodarone and thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    who are also being treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the consequences of amiodarone-induced thyroid dysfunction include a significant influence on warfarin response. The effect of warfarin is potentiated by thyrotoxicosis and attenuated in hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/15\">",
"     15",
"    </a>",
"    ]. In any patient with amiodarone-induced thyroid dysfunction who is also taking warfarin, the International Normalized Ratio (INR) should be monitored closely and appropriate adjustments in warfarin dosing made. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CARDIAC TOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sinus bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    can directly cause both sinus bradycardia and AV nodal block, due primarily to its calcium channel blocking activity. The overall incidence of bradycardic events has been about 5 percent (",
"    <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/3\">",
"     3",
"    </a>",
"    ]. In the meta-analysis cited above of chronic low-dose amiodarone (mean 150 to 330",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    the incidence of bradycardic events was significantly greater than with placebo (3.3 versus 1.4 percent, OR 2.2, 95 CI 1.1 to 4.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bradycardia requiring a permanent pacemaker with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy appears to be a particular concern with amiodarone in elderly patients with atrial fibrillation who have had a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/16\">",
"     16",
"    </a>",
"    ], and may also be of greater concern in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/17\">",
"     17",
"    </a>",
"    ]. Pacing to maintain continuous and homogeneous activation of the atria in such patients also may reduce the frequency of AF recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5367?source=see_link\">",
"     \"The role of pacemakers in the prevention of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of greater potential concern is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced prolongation of repolarization and the QT interval due to blockade of the potassium channels. Ventricular arrhythmias may arise in this setting due to early afterdepolarization-dependent triggered activity. However, the incidence of proarrhythmia is very low with amiodarone, with an incidence of torsades de pointes below 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/18\">",
"     18",
"    </a>",
"    ]. In the meta-analysis of low-dose therapy, there were no cases of torsades de pointes in the 738 patients treated with amiodarone for at least one year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    has much less of this proarrhythmic effect than other class III drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , particularly when given in lower doses (",
"    <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ]. Several factors contribute to the rarity of TdP with amiodarone: lack of reverse use dependence; concurrent blockade of the L-type calcium channels; and less heterogeneity of ventricular repolarization (less QT dispersion). However, the exact electrophysiologic mechanisms responsible for the low proarrhythmic activity of amiodarone are incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Torsades de pointes associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy is more likely to occur in women and is much more likely to occur with other factors that can cause QT prolongation such as hypokalemia, hypomagnesemia, and certain antiarrhythmic drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/21\">",
"     21",
"    </a>",
"    ]. Female preponderance with torsades de pointes has also been noted with other antiarrhythmic drugs, with noncardiac drugs, and with congenital long QT syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H10#H10\">",
"     \"Acquired long QT syndrome\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H2157420#H2157420\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Age and sex'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    does not worsen left ventricular systolic function and can be used to treat ventricular arrhythmias in selected patients with heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2159259\">",
"    <span class=\"h2\">",
"     Interaction with ICDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    may have important interactions with implantable cardioverter-defibrillators (ICDs). It may slow the ventricular tachycardia rate, possibly precluding its recognition by the device, and its major metabolite desethylamiodarone increases the defibrillation threshold in a dose-dependent fashion; this effect is seen with monophasic and biphasic waveforms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. The NASPE guidelines for amiodarone therapy recommend that, whenever amiodarone is initiated in a patient with an ICD, a noninvasive ICD evaluation or an electrophysiology study should be performed to test for adverse drug-device interactions once loading is complete [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H27#H27\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Antiarrhythmic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2159346\">",
"    <span class=\"h2\">",
"     Toxicity in patients without an ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since not all patients at risk for sudden cardiac arrest (SCA) are eligible for, or have access to implantable cardioverter defibrillators (ICD), the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    for the prevention of SCA has been considered. A meta-analysis of all randomized controlled trials examining the use of amiodarone versus",
"    <span class=\"nowrap\">",
"     placebo/control",
"    </span>",
"    for the prevention of SCD revealed that amiodarone reduces the risk of SCA by 29 percent and cardiovascular death by 18 percent and is a viable alternative in patients who are not eligible for or who do not have access to ICD therapy for the prevention of SCA. However, amiodarone therapy is associated with a two- and fivefold increased risk of pulmonary and thyroid toxicity respectively in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    has not been thought to increase mortality, even in patients with underlying heart failure or coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, a significant increase in mortality has been suggested in patients with New York Heart Association class III heart failure who were treated with amiodarone. This possible effect was noted in a subset analysis from the SCD-HeFT trial of patients with New York Heart Association class II or III HF and a left ventricular ejection fraction &le;35 percent and, in a preliminary post hoc analysis, from the VALIANT trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    in patients with HF occurring within 10 days after an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link&amp;anchor=H2#H2\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\", section on 'Type of arrhythmia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HEPATOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transient rise in serum aminotransferase concentrations occurs in approximately 25 percent (range 15 to 50 percent) of patients soon after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is begun [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/30\">",
"     30",
"    </a>",
"    ]. The patients are usually asymptomatic, but the drug should be discontinued if there is more than a two-fold elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/3\">",
"     3",
"    </a>",
"    ]. Symptomatic hepatitis occurs in less than 3 percent of patients; potential complications include cirrhosis and hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. As a result, it is recommended that liver function tests be monitored at baseline and every six months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Jaundice is an unusual side effect that may be due to intrahepatic cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Serum bilirubin concentrations may first increase or continue to increase for a period of time after the drug is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. These findings are consistent with the long half-life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (25 to 100 days).",
"   </p>",
"   <p>",
"    The histopathologic features of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced hepatotoxicity include Mallory bodies, steatosis, intralobular inflammatory infiltrates, fibrosis, and phospholipidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/30,34-37\">",
"     30,34-37",
"    </a>",
"    ]. These changes are similar to those in alcoholic liver disease. The presence of phospholipid-laden lysosomal lamellar bodies on electron microscopy may help distinguish amiodarone hepatotoxicity from alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both direct hepatotoxicity and metabolic idiosyncrasy are thought to contribute to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/30,37\">",
"     30,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The phospholipidosis is thought to reflect an interaction between phospholipid and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , leading to the formation of a complex that prevents degradation of phospholipid molecules. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link&amp;anchor=H15#H15\">",
"       \"Drugs and the liver: Patterns of drug-induced liver injury\", section on 'Phospholipidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic idiosyncrasy refers to the propensity of a patient to produce toxic metabolites from a compound to a greater degree than other individuals. The site of abnormal drug metabolism is probably the hepatocyte. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=see_link&amp;anchor=H1660400127#H1660400127\">",
"       \"Drugs and the liver: Metabolism and mechanisms of injury\", section on 'Metabolic'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the relation of hepatotoxicity to cumulative dose and duration of therapy is uncertain, it is likely that cumulative dose correlates with overall toxicity and, therefore, that maintenance doses should be kept as low as possible. In the meta-analysis cited above of chronic low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (mean 150 to 330",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    the incidence of hepatotoxicity was low and not significantly different from placebo (1.2 versus 0.8 percent, OR 1.2, 95 CI 0.4 to 3.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OCULAR CHANGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Corneal microdeposits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneal microdeposits occur in most patients receiving long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy, while some patients also develop lenticular opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The corneal microdeposits are caused by the secretion of amiodarone by the lacrimal gland with accumulation on the corneal surface. They are identifiable on ophthalmologic examination as a brownish whorl at the juncture of the lower",
"    <span class=\"nowrap\">",
"     1/3",
"    </span>",
"    and upper",
"    <span class=\"nowrap\">",
"     2/3",
"    </span>",
"    of the cornea and have been described as resembling a cat's whiskers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/38\">",
"     38",
"    </a>",
"    ]. The formation of microdeposits is dose-dependent; the changes are reversible within seven months after amiodarone is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Corneal microdeposits do not reduce visual acuity. However, ocular symptoms occur in a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. These include halo vision (colored rings around lights), particularly at night, photophobia, and blurred vision. The incidence was 6 percent in an early study compared to only 1.5 percent in a later meta-analysis of trials of chronic low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (mean dose 150 to 330",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2,39\">",
"     2,39",
"    </a>",
"    ]. This value was still significantly greater than seen with placebo (0.1 percent, OR 3.4, 95 CI 1.2 to 9.6).",
"   </p>",
"   <p>",
"    The presence of microdeposits is not considered a contraindication to continued",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy, since visual acuity is rarely affected [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In any patient with visual symptoms who is taking amiodarone, other common factors (a change in refractive correction, progression of age-related cataract, or increased intraocular pressure) should be considered before attributing the change to the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Optic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    has been reported to cause optic nerve injury, with unilateral or bilateral visual loss that can progress to permanent blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/38,41\">",
"     38,41",
"    </a>",
"    ]. The prevalence of this finding may be as high as 1 to 2 percent after 10 years of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/38\">",
"     38",
"    </a>",
"    ]. Histopathologic studies have demonstrated lamellar inclusions in the large axons of the retrobulbar optic nerve, suggesting a drug-induced lipidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/42\">",
"     42",
"    </a>",
"    ]. However, a causal relationship to amiodarone use has not been clearly established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cessation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or dose reduction is recommended unless the arrhythmia is life-threatening and an alternative antiarrhythmic drug is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    has a number of other toxic effects (",
"    <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Skin reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin reactions are common with long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy. These include photosensitivity, which can be treated with avoidance of sun exposure and the use of sunblock, and a bluish-slate gray discoloration of the skin (so-called \"blue man syndrome\"), which is usually most prominent on the face (",
"    <a class=\"graphic graphic_picture graphicRef70419 \" href=\"UTD.htm?36/61/37842\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The NASPE guidelines suggested that photosensitivity occurred in 25 to 75 percent of patients and skin discoloration in less than 10 percent (",
"    <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/3\">",
"     3",
"    </a>",
"    ]. However, a much lower rate of 2.3 percent was noted in the meta-analysis of trials of chronic low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy (mean dose 150 to 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2\">",
"     2",
"    </a>",
"    ]. This value was still significantly greater than seen with placebo (0.7 percent, OR 2.5, 95 CI 1.1 to 6.2).",
"   </p>",
"   <p>",
"    The bluish-slate gray discoloration of the skin occurs in 1 to 3 percent of patients on chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy and appears to be due to the deposition of lipofuscin in the dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. There may be a tissue threshold for amiodarone in individual patients above which skin discoloration appears and below which it fades [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, patients disturbed by skin pigmentation who are taking large doses (more than 400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may notice improvement in skin discoloration by reducing the dose.",
"   </p>",
"   <p>",
"    There is no specific therapy for the skin discoloration, but affected patients are advised to avoid sun exposure. Complete resolution after cessation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy may take one year or more [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gastrointestinal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal side effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy include nausea, vomiting, anorexia, diarrhea, and constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. They have been described in up to 30 percent of patients (",
"    <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"     table 1",
"    </a>",
"    ), mostly during the initial loading phase of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/3\">",
"     3",
"    </a>",
"    ]. In the meta-analysis of trials of chronic low-dose amiodarone therapy, gastrointestinal side effects were not significantly more frequent than with placebo (4.2 versus 3.3 percent, OR 1.1, 95 CI 0.6 to 1.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neurologic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic toxicity may take many forms including tremor, ataxia, peripheral neuropathy with paresthesias, and sleep disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These effects, which have been described in 3 to 30 percent of patients (",
"    <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"     table 1",
"    </a>",
"    ), appear to be dose-related, being more common during initial loading or in patients requiring higher doses. In the meta-analysis of trials of chronic low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy (mean dose 150 to 330",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    neurologic side effects were much less common than what was reported in early studies that utilized higher doses of amiodarone, but still significantly more frequent than with placebo (4.6 versus 1.9 percent, OR 2.0, 95% CI 1.1-3.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/2\">",
"     2",
"    </a>",
"    ]. A retrospective study of 707 patients in Olmsted County treated with amiodarone arrived at a similar conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Genitourinary effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sterile epididymitis with pain or swelling in the scrotum and sexual dysfunction has been described in a small number of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Among patients with epididymitis, reducing the amiodarone dose can prevent unnecessary antibiotic therapy and invasive urologic procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Changes in serum lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in serum lipid concentrations have been noted in some",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -treated patients. Amiodarone increases serum cholesterol and triglyceride concentrations, but also raises serum high density lipoprotein cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Given these counterbalancing effects, it is uncertain if amiodarone has an adverse effect on coronary risk.",
"   </p>",
"   <p>",
"    How these changes occur is uncertain. The changes in serum cholesterol and triglycerides resemble those seen in hypothyroidism, suggesting that the reductions in plasma and tissue T3 may contribute. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28550?source=see_link\">",
"     \"Lipid abnormalities in thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     USE IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    may cause toxicity in either the mother or the fetus. Its use in pregnancy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link&amp;anchor=H5990251#H5990251\">",
"     \"Clinical uses of amiodarone\", section on 'Use in pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    can interfere with the hepatic metabolism of several antiarrhythmic drugs (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ), possibly leading to supratherapeutic plasma concentrations if the dose is not reduced. It also predictably interferes with the metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , often requiring at least a 25 percent reduction in warfarin dose [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/53\">",
"     53",
"    </a>",
"    ]. These interactions are particularly worrisome because they may persist for as long as three months after the cessation of therapy due to the long elimination half-life of amiodarone (25 to 100 days). (See Lexi-Interact&trade; program included with UpToDate for additional information including specific dose adjustments [or limits] and management suggestions). (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     \"Amiodarone: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The interaction between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is further complicated by the potential effects of amiodarone on thyroid function. The effect of warfarin is potentiated by thyrotoxicosis and attenuated in hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/15\">",
"     15",
"    </a>",
"    ]. Thyroid function should be reassessed in any patient on a stable warfarin and amiodarone regimen if the International Normalized Ratio (INR) changes unexpectedly. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Thyroid dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     FOLLOW-UP AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long half-life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (25 to 100 days) and the potential severity of some of the adverse effects make early recognition important. As a result, careful monitoring of patients taking amiodarone is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Oral amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations from the NASPE guidelines, including routine laboratory testing, are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef50410 \" href=\"UTD.htm?1/55/1917\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23449/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Intravenous amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is generally used in the management of life-threatening ventricular arrhythmias or in critically ill patients with AF. Thus, most patients receiving IV amiodarone are on continuous electrocardiographic monitoring with frequent assessment of vital signs. Such monitoring is appropriate in all patients due to the potential for hypotension and arrhythmias (eg, torsades de pointes or bradycardia due to AV block or conversion to sinus rhythm with sinus bradycardia). In addition, the usual baseline laboratories should be obtained (",
"    <a class=\"graphic graphic_table graphicRef50410 \" href=\"UTD.htm?1/55/1917\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2158832\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is primarily given for short-term management of serious ventricular arrhythmias and has a different electrophysiologic and pharmacologic profile from oral amiodarone. The one common problem noted with intravenous amiodarone is hypotension, which can occur in up to 26 percent of patients. However, many of the adverse effects associated with oral amiodarone described below are due to tissue accumulation of the drug with long-term therapy and are not seen with short-term use of intravenous amiodarone. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Intravenous amiodarone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary toxicity generally correlates more closely with the total cumulative dose than with serum drug levels, usually occurring months to years after the initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      therapy. Several different types of pulmonary toxicity may result from chronic amiodarone use, including chronic interstitial pneumonitis (the most common), organizing pneumonia, acute respiratory distress syndrome, and a solitary pulmonary mass. A nonproductive cough and dyspnea are present in the majority of affected individuals at presentation, and pleuritic pain, weight loss, fever (33 to 50 percent of cases), and malaise can also occur. The physical examination often reveals bilateral inspiratory crackles. The diagnosis of amiodarone pulmonary toxicity is one of exclusion. Treatment consists primarily of stopping amiodarone, with corticosteroid therapy administered in patients with symptomatic pulmonary toxicity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pulmonary disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29767?source=see_link\">",
"       \"Amiodarone pulmonary toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thyroid dysfunction (including both hypothyroidism and hyperthyroidism) is a common complication of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      therapy, occurring in about 3 to 4 percent of patients when lower doses (&lt;400",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      are used (",
"      <a class=\"graphic graphic_table graphicRef57845 \" href=\"UTD.htm?5/11/5309\">",
"       table 1",
"      </a>",
"      ). Underlying thyroid status and iodine intake appear to influence the incidence and type of thyroid dysfunction seen with amiodarone therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Thyroid dysfunction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=see_link\">",
"       \"Amiodarone and thyroid dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In up to 5 percent of patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      can directly cause both sinus bradycardia and AV nodal block, due primarily to its calcium channel blocking activity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Sinus bradycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a theoretical concern for proarrhythmia with the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      because of its prolongation of repolarization and the QT interval due to blockade of the potassium channels. However, the incidence of proarrhythmia is very low with amiodarone, with an incidence of torsades de pointes below 1 percent per year. When torsades de pointes does occurs with the use of amiodarone, it is much more likely to occur with other factors that can cause QT prolongation such as hypokalemia, hypomagnesemia, and concomitant use of certain other antiarrhythmic drugs. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ventricular arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A transient rise in serum aminotransferase concentrations occurs in approximately 25 percent (range 15 to 50 percent) of patients soon after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is begun. However, symptomatic hepatitis occurs in less than 3 percent of patients, and potential complications such as cirrhosis and hepatic failure occur very infrequently. Although the relation of hepatotoxicity to cumulative dose and duration of therapy is uncertain, it is likely that cumulative dose correlates with overall toxicity. While patients are usually asymptomatic, the drug should be discontinued if there is more than a twofold elevation in serum aminotransferases. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hepatotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Corneal microdeposits occur in most patients receiving long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      therapy, while some patients also develop lenticular opacities. While corneal microdeposits do not reduce visual acuity, ocular symptoms may occur, including halo vision (colored rings around lights), photophobia, and blurred vision. The presence of microdeposits is not considered a contraindication to continued amiodarone therapy since visual acuity is rarely affected. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Corneal microdeposits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of other side effects can manifest with the chronic use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , including dermatologic (photosensitivity and skin discoloration), gastrointestinal (nausea, vomiting, anorexia, diarrhea, constipation), neurologic (tremor, ataxia), genitourinary (epididymitis), and altered lipid concentrations. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      can interfere with the hepatic metabolism of several antiarrhythmic drugs (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      ), possibly leading to supratherapeutic plasma concentrations if the dose is not reduced. It also predictably interferes with the metabolism of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , often requiring at least a 25 percent reduction in warfarin dose. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The long half-life of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (25 to 100 days) and the potential severity of some of the adverse effects make early recognition important. As a result, careful monitoring of patients taking amiodarone is essential (",
"      <a class=\"graphic graphic_table graphicRef50410 \" href=\"UTD.htm?1/55/1917\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Follow-up and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/1\">",
"      Greene HL, Graham EL, Werner JA, et al. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 1983; 2:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/2\">",
"      Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/3\">",
"      Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/4\">",
"      Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997; 127:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/5\">",
"      Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/6\">",
"      Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med 1995; 122:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/7\">",
"      Gallik DM, Singer I, Meissner MD, et al. Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone. Am J Cardiol 2002; 90:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/8\">",
"      Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest 1988; 93:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/9\">",
"      Kharabsheh S, Abendroth CS, Kozak M. Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Am J Cardiol 2002; 89:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/10\">",
"      Mason JW. Amiodarone. N Engl J Med 1987; 316:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/11\">",
"      Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/12\">",
"      Mason JW. Prediction of amiodarone-induced pulmonary toxicity. Am J Med 1989; 86:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/13\">",
"      Gleadhill IC, Wise RA, Schonfeld SA, et al. Serial lung function testing in patients treated with amiodarone: a prospective study. Am J Med 1989; 86:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/14\">",
"      Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984; 101:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/15\">",
"      Kurnik D, Loebstein R, Farfel Z, et al. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004; 83:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/16\">",
"      Essebag V, Hadjis T, Platt RW, Pilote L. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J Am Coll Cardiol 2003; 41:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/17\">",
"      Essebag V, Reynolds MR, Hadjis T, et al. Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation. Arch Intern Med 2007; 167:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/18\">",
"      Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994; 121:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/19\">",
"      Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995; 6:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/20\">",
"      van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001; 104:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/21\">",
"      Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/22\">",
"      Goldschlager N, Epstein A, Friedman P, et al. Environmental and drug effects on patients with pacemakers and implantable cardioverter/defibrillators: a practical guide to patient treatment. Arch Intern Med 2001; 161:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/23\">",
"      Zhou L, Chen BP, Kluger J, et al. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998; 31:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/24\">",
"      Pelosi F Jr, Oral H, Kim MH, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000; 11:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/25\">",
"      Nielsen TD, Hamdan MH, Kowal RC, et al. Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. Am J Cardiol 2001; 88:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/26\">",
"      Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009; 30:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/27\">",
"      Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/28\">",
"      Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.",
"     </a>",
"    </li>",
"    <li>",
"     www.theheart.org/viewArticle.do?primaryKey=460115&amp;nl_id=tho25may05#bib_1 (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/30\">",
"      Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/31\">",
"      Richer M, Robert S. Fatal hepatotoxicity following oral administration of amiodarone. Ann Pharmacother 1995; 29:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/32\">",
"      Chang CC, Petrelli M, Tomashefski JF Jr, McCullough AJ. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. Arch Pathol Lab Med 1999; 123:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/33\">",
"      Macarri G, Feliciangeli G, Berdini V, et al. Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Ital J Gastroenterol 1995; 27:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/34\">",
"      Simon JB, Manley PN, Brien JF, Armstrong PW. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 1984; 311:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/35\">",
"      Rigas B, Rosenfeld LE, Barwick KW, et al. Amiodarone hepatotoxicity. A clinicopathologic study of five patients. Ann Intern Med 1986; 104:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/36\">",
"      Poucell S, Ireton J, Valencia-Mayoral P, et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 1984; 86:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/37\">",
"      Somani P, Bandyopadhyay S, Klaunig JE, Gross SA. Amiodarone- and desethylamiodarone-induced myelinoid inclusion bodies and toxicity in cultured rat hepatocytes. Hepatology 1990; 11:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/38\">",
"      M&auml;ntyj&auml;rvi M, Tuppurainen K, Ik&auml;heimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998; 42:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/39\">",
"      Ingram DV. Ocular effects in long-term amiodarone therapy. Am Heart J 1983; 106:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/40\">",
"      Flach AJ, Dolan BJ. Progression of amiodarone induced cataracts. Doc Ophthalmol 1993; 83:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/41\">",
"      Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999; 127:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/42\">",
"      Mansour AM, Puklin JE, O'Grady R. Optic nerve ultrastructure following amiodarone therapy. J Clin Neuroophthalmol 1988; 8:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/43\">",
"      Enseleit F, Wyss CA, Duru F, et al. Images in cardiovascular medicine. The blue man: amiodarone-induced skin discoloration. Circulation 2006; 113:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/44\">",
"      Alinovi A, Reverberi C, Melissari M, Gabrielli M. Cutaneous hyperpigmentation induced by amiodarone hydrochloride. J Am Acad Dermatol 1985; 12:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/45\">",
"      Delage C, Lagac&eacute; R, Huard J. Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study. Can Med Assoc J 1975; 112:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/46\">",
"      Kounis NG, Frangides C, Papadaki PJ, et al. Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation. Clin Cardiol 1996; 19:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/47\">",
"      Blackshear JL, Randle HW. Reversibility of blue-gray cutaneous discoloration from amiodarone. Mayo Clin Proc 1991; 66:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/48\">",
"      Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009; 66:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/49\">",
"      Hamoud K, Kaneti J, Smailowitz Z, Lissmer L. Amiodarone-induced epididymitis. Report of 2 cases. Eur Urol 1996; 29:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/50\">",
"      Ahmad S. Amiodarone and sexual dysfunction. Am Heart J 1995; 130:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/51\">",
"      Pollak PT, Sharma AD, Carruthers SG. Elevation of serum total cholesterol and triglyceride levels during amiodarone therapy. Am J Cardiol 1988; 62:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/52\">",
"      Pollak PT, Tan MH. Elevation of high-density lipoprotein cholesterol in humans during long-term therapy with amiodarone. Am J Cardiol 1999; 83:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23449/abstract/53\">",
"      Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. Chest 2002; 121:19.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 931 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23449=[""].join("\n");
var outline_f22_57_23449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2158832\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTRAVENOUS AMIODARONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PULMONARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Preexisting pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THYROID DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CARDIAC TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2159259\">",
"      Interaction with ICDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2159346\">",
"      Toxicity in patients without an ICD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HEPATOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OCULAR CHANGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Corneal microdeposits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Skin reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gastrointestinal side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neurologic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Genitourinary effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Changes in serum lipids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      USE IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      FOLLOW-UP AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Oral amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Intravenous amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2158832\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/931\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/931|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/60/21441\" title=\"picture 1\">",
"      BAL amiodarone lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/61/37842\" title=\"picture 2\">",
"      Amiodarone skin pigmentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/931|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/11/5309\" title=\"table 1\">",
"      Side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/55/1917\" title=\"table 2\">",
"      Monitor during amiodarone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=related_link\">",
"      Amiodarone and thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29767?source=related_link\">",
"      Amiodarone pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=related_link\">",
"      Amiodarone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=related_link\">",
"      Drugs and the liver: Metabolism and mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28550?source=related_link\">",
"      Lipid abnormalities in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5367?source=related_link\">",
"      The role of pacemakers in the prevention of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_57_23450="Epidemiology and pathogenesis of amyotrophic lateral sclerosis";
var content_f22_57_23450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of amyotrophic lateral sclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/57/23450/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23450/contributors\">",
"     Nicholas J Maragakis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23450/contributors\">",
"     Nestor Galvez-Jimenez, MD, MSc, MHSA, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/57/23450/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23450/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23450/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/57/23450/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/57/23450/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/57/23450/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyotrophic lateral sclerosis (ALS), first described by Charcot in the nineteenth century [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/1\">",
"     1",
"    </a>",
"    ], is a relentlessly progressive neurodegenerative disorder that causes muscle weakness, disability, and eventually death, with a median survival of three to five years. ALS is also known by the eponym \"Lou Gehrig's Disease,\" after the famous baseball player who was affected with the disorder. Motor neuron disease (MND) is the preferred term in the United Kingdom, but in the United States ALS and MND are sometimes used interchangeably.",
"   </p>",
"   <p>",
"    Historically, ALS was identified as a clinical syndrome distinguishable from other motor neuron diseases such as primary lateral sclerosis (PLS), primary muscular atrophy (PMA), and progressive bulbar palsy (PBP), based upon the location of first symptom and the extent to which anterior horn cells or corticomotor neurons were initially involved. It is becoming increasingly evident, however, that these diseases may share a common pathophysiology and, most likely, a common etiology as well. Advances in neurogenetics have distinguished spinal muscular atrophy from other motor neuron diseases, as well as the X-linked disorder bulbospinal muscular atrophy (Kennedy disease).",
"   </p>",
"   <p>",
"    It is also increasingly recognized that ALS may affect other cortical neurons, in addition to motor neurons (as in frontotemporal dementia with ALS), appropriately placing ALS among the other neurodegenerative diseases such as Alzheimer disease, Parkinson disease, and Huntington disease.",
"   </p>",
"   <p>",
"    The epidemiology and pathogenesis of ALS are discussed in this topic review. Other aspects of ALS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link\">",
"     \"Familial amyotrophic lateral sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyotrophic lateral sclerosis (ALS) is classified as either sporadic or familial:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sporadic forms account for 90 to 95 percent of ALS cases.",
"     </li>",
"     <li>",
"      Familial forms make up 5 to 10 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link\">",
"       \"Familial amyotrophic lateral sclerosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence and prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incidence rates for ALS in Europe and North America range between 1.5 and 2.7 per",
"    <span class=\"nowrap\">",
"     100,000/year,",
"    </span>",
"    while prevalence rates range between 2.7 and 7.4 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A systematic review of global epidemiologic data concluded that the incidence of ALS may be lower among African, Asian, and Hispanic ethnic groups than among Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/4\">",
"     4",
"    </a>",
"    ]. However, firm conclusions were precluded by the methodologic variation among studies that evaluated non-Caucasian populations.",
"   </p>",
"   <p>",
"    The male to female ratio is about 1.3 to 1.5 for sporadic ALS, although the ratio becomes closer to unity in the age group over 70 years. The incidence of ALS increases with each decade, especially after age 40 years, and it peaks at age 74, decreasing thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/2\">",
"     2",
"    </a>",
"    ]. In the United States, about 7000 new cases of ALS are diagnosed each year.",
"   </p>",
"   <p>",
"    The incidence and mortality rates of ALS have been slowly increasing over decades [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Part or all of this increase in ALS incidence may be due to longer life expectancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only established risk factors for ALS are age and family history. Accumulating evidence suggests that cigarette smoking is also a risk factor for ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The role of genetic variation in the pathogenesis of sporadic ALS is reviewed below. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Genetic susceptibility in sporadic ALS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are weak or conflicting data for other putative nongenetic risk factors, a list that includes military service, agricultural work, factory work, heavy manual labor, exposure to welding or soldering, exposure to heavy metal, work in the plastics industry, repetitive muscle use, athleticism, playing professional soccer, trauma, and electrical shock [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/12-25\">",
"     12-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite reports of exposure to mercury, lead, and aluminum in ALS cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/13,18\">",
"     13,18",
"    </a>",
"    ], the role of heavy metal exposure in the etiology of ALS remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. No convincing case of lead toxicity mimicking ALS has been reported in several decades [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/19\">",
"     19",
"    </a>",
"    ]. However, there is evidence suggesting that lead exposure modifies the risk of developing ALS. A number of case-control studies using questionnaire data have reported an association between occupational exposure to lead and ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/22\">",
"     22",
"    </a>",
"    ]. Furthermore, a study using both questionnaire data and biological samples from blood and bone found an association between lead levels and ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/21\">",
"     21",
"    </a>",
"    ]. While recall bias may confound interpretation of these reports, the theory that lead exposure plays a role in the etiology of ALS merits further investigation.",
"   </p>",
"   <p>",
"    The possible role of environmental exposure as an ALS trigger is supported by the finding that the incidence of ALS in young US Gulf War veterans is about a two-fold higher than expected [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The risk ratio for developing ALS was statistically significant in Army and Air Force veterans, while a trend toward increased risk for veterans of the Reserves, National Guard, Marines, and Navy did not reach statistical significance, possibly because of the relatively small number of subjects in those branches. Despite the higher incidence among Gulf War veterans, no common link was identified among potential exposures or activities in veterans who developed ALS. Because ALS is a relatively rare disease, the strength of these findings is reduced by the small number of cases and potential methodological flaws [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent, large cohort study of men (median age 57 years at cohort entry in 1982) found that US military veterans had an increased death rate from ALS compared with non-veterans (adjusted relative risk 1.58, 95% CI 1.14-2.19) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/25\">",
"     25",
"    </a>",
"    ]. As with previous studies, this higher incidence seemed independent of the branch of the military in which subjects served, except for the Marines, a subgroup with a small number of subjects. The increased risk of death from ALS was similar in veterans who served in the military during World War II, Korea, or Vietnam. There was no association between risk for developing ALS and the number of years served in the military. This result argues against a specific environmental trigger related to the Gulf War being a cause of ALS, since the association with ALS in the larger cohort study was largely independent of the time period of military service.",
"   </p>",
"   <p>",
"    The potential risk factors that military personnel would share over the many decades of military service studied are numerous and include inhalation of aerosolized lead used in vehicle finishing operations, exposure to the pesticide DEET, traumatic injuries, viral infections, and intense physical activity. However, none of these are established as risk factors, and confirmation of these factors awaits further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic susceptibility in sporadic ALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several gene mutations that cause familial ALS, including mutations in the SOD1, TARDBP, C9ORF72, ANG, FUS, OPTN, and SETX genes, have also been identified in occasional patients with sporadic ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/27-34\">",
"     27-34",
"    </a>",
"    ]. Mutations in the SQSTM1 gene have likewise been described in both familial and sporadic ALS, although the precise role of this gene in the pathogenesis of ALS is not well defined [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2012 study that screened 480 consecutive patients with sporadic ALS, mutations in genes associated with familial ALS were detected in 45 patients (9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/33\">",
"     33",
"    </a>",
"    ]. The most frequently detected mutations involved the TARDBP, C9ORF72, and SOD1 genes (2.7, 2.5, and 2.1 percent, respectively). Thus, these genes may function as Mendelian genes in familial ALS or as low-penetrance susceptibility factors in sporadic ALS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link\">",
"     \"Familial amyotrophic lateral sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not described in familial ALS, intermediate length polyglutamine expansions in the ataxin 2 gene (ATXN2) are associated with an increased risk of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Among 480 consecutive patients with sporadic ALS, mutations in ATXN2 were identified in 8 patients (1.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/33\">",
"     33",
"    </a>",
"    ]. Expanded polyglutamine repeats in ATXN2 are better known as the cause of spinocerebellar ataxia type 2 (SCA2). One issue is that occasional patients with SCA2 have a predominant phenotype of motor neuron disease, and further study is needed to establish whether ATXN2 polyglutamine expansions are a risk factor for ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=see_link&amp;anchor=H6#H6\">",
"     \"The spinocerebellar ataxias\", section on 'SCA2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accumulating data suggest that duplication of the survival motor neuron 1 (SMN1) gene is a risk factor for adult-onset sporadic ALS, while survival motor neuron 2 (SMN2) gene copy number status is not [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/42\">",
"     42",
"    </a>",
"    ]. The largest genetic association study, which evaluated 847 patients with ALS and 984 controls, found a significant association of SMN1 duplications with ALS susceptibility (odds ratio [OR] 2.07, 95% CI 1.34-3.20) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/43\">",
"     43",
"    </a>",
"    ]. A meta-analysis of this study and previous data [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/44-46\">",
"     44-46",
"    </a>",
"    ] showed a similar association (OR 1.85, 95% CI 1.18-2.90) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/43\">",
"     43",
"    </a>",
"    ]. In contrast, SMN1 deletions and survival motor neuron 2 (SMN2) gene copy numbers were not significantly associated with ALS. The SMN gene is better known for its role in spinal muscular atrophy, a disease of neonatal or childhood onset characterized by degeneration of the anterior horn cells in the spinal cord and motor nuclei in the lower brainstem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=see_link\">",
"     \"Spinal muscular atrophy\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Apart from the genes described above, the role of genetic variation in the pathogenesis of sporadic ALS remains elusive. However, genome-wide association studies and candidate gene studies have identified several putative genetic susceptibility loci for sporadic ALS, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a genome-wide association study of 386 patients of European descent with ALS and 542 controls, statistically significant associations with sporadic ALS were found for 10 genetic loci that could be confirmed in two additional independent populations of case patients and controls [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/47\">",
"       47",
"      </a>",
"      ]. Furthermore, another 41 loci had statistically significant associations in two of the three populations. The results suggest that there may be numerous low-risk genetic susceptibility loci for sporadic ALS.",
"     </li>",
"     <li>",
"      In another genome-wide association study from the Netherlands involving 461 patients with ALS and 451 controls, a genetic variant of the ITPR2 gene was associated with ALS, and the association was confirmed in a second analysis that involved a further 876 patients with ALS and 906 controls from Northern Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these and similar studies provide clues to identifying possible susceptibility genes for sporadic ALS, they are not definitive, and further research is needed to confirm and extend these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Familial ALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial ALS accounts for 5 to 10 percent of all ALS cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/51\">",
"     51",
"    </a>",
"    ], with the rest being sporadic (idiopathic) in origin. Familial ALS is phenotypically and genetically heterogeneous. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link\">",
"     \"Familial amyotrophic lateral sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Geographic clusters",
"    </span>",
"    &nbsp;&mdash;&nbsp;High prevalence clusters of ALS are found in three regions of the western Pacific including Guam, West New Guinea, and the Kii Peninsula in Japan. The first cluster described was found in the indigenous people of Guam [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The frequent association of ALS with parkinsonism and Alzheimer disease in this population has led to the designation of this entity as the amyotrophic lateral sclerosis-parkinsonism dementia complex (ALS-PDC).",
"   </p>",
"   <p>",
"    Although intensively studied since World War II, the cause of Guamanian ALS-PDC is unknown. One hypothesis proposed that the neurotoxicity was mediated by the local dietary consumption of cycad (Cycas circinalis) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/54\">",
"     54",
"    </a>",
"    ]. Cycad is rich in beta-N-methylamino-L-alanine (BMAA), an excitatory amino acid that has been shown to induce neuronal cell death in the rhesus monkey [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/54\">",
"     54",
"    </a>",
"    ]. Another hypothesis proposed that human consumption of the local flying fox, an animal that forages on the cycad, may have generated sufficiently high and cumulative levels of the neurotoxin to cause ALS-PDC. This hypothesis was supported by data demonstrating that the incidence of ALS-PDC on Guam fell significantly and in parallel with the loss of population of the flying fox [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/55\">",
"     55",
"    </a>",
"    ]. However, many remain unconvinced that cycad ingestion is the cause of Guamanian ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/56\">",
"     56",
"    </a>",
"    ]. No single genetic defect, environmental toxin, or virus has been convincingly linked to these cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALS is characterized by motor neuron degeneration and death with gliosis replacing lost neurons. Cortical motor cells (pyramidal and Betz cells) disappear leading to retrograde axonal loss and gliosis in the corticospinal tract. This gliosis results in the bilateral white matter changes sometimes seen in the brain magnetic resonance imaging (MRI) of patients with ALS. The spinal cord becomes atrophic. The ventral roots become thin, and there is a loss of large myelinated fibers in motor nerves. The affected muscles show denervation atrophy with evidence of reinnervation such as fiber type grouping.",
"   </p>",
"   <p>",
"    Additional pathologic findings may include a loss of frontal or temporal cortical neurons, particularly in ALS with frontotemporal dementia (ALS-FTD). Mounting evidence from pathologic and genetic studies has led to the hypothesis that similar molecular pathways are involved in both disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link&amp;anchor=H1808661#H1808661\">",
"     \"Familial amyotrophic lateral sclerosis\", section on 'C9ORF72 gene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loss of non-motor neurons whose axons contribute to the descending fronto-ponto-cerebellar tract has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/57\">",
"     57",
"    </a>",
"    ]. Pathology in non-motor systems such as the posterior columns may be seen in familial forms of ALS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link\">",
"     \"Familial amyotrophic lateral sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While sensory involvement is not obvious clinically, the density of myelinated sensory fibers is reduced by approximately 30 percent in peripheral nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intracellular inclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracellular inclusions in degenerating neurons and glia are frequent neuropathological findings of ALS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phosphorylated and nonphosphorylated neurofilament inclusions are prominent in spinal motor neurons; these may be associated with immunoreactive SOD1, even in sporadic ALS, or with nitric oxide.",
"     </li>",
"     <li>",
"      Bunina bodies are unique to ALS and consist of eosinophilic aggregates that are positive for cystatin C, a cysteine protease inhibitor.",
"     </li>",
"     <li>",
"      Ubiquinated inclusions are seen in ALS and several other neurodegenerative disorders, including frontotemporal dementia (FTD) with ubiquitin",
"      <span class=\"nowrap\">",
"       positive/tau",
"      </span>",
"      negative inclusions, but the ALS variety is unique in that it does not react with antibodies against neurofilament or tau. In both the familial or sporadic types of ALS-FTD, frontal and temporal lobe ubiquinated inclusions are found in cortical neurons. Inclusions may be absent in some genetic forms of FALS [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The TAR DNA binding protein 43 (TDP-43) has been identified as a major component of ubiquinated inclusions in sporadic ALS, frontotemporal dementia (FTD) with ubiquitin-positive but tau-negative inclusions, ALS with frontotemporal dementia, and non-SOD1 familial ALS [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/60-64\">",
"       60-64",
"      </a>",
"      ]. However, TDP-43 inclusions are not found in mutant SOD1-related familial ALS, with a few exceptions [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. In addition, mutations in the TARDBP gene that encodes TDP-43 are known to cause one type of autosomal dominant familial ALS (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link&amp;anchor=H10#H10\">",
"       \"Familial amyotrophic lateral sclerosis\", section on 'ALS10 (TARDBP gene)'",
"      </a>",
"      ). These findings suggest a potentially important role for TDP-43 in the pathogenesis of ALS, non-SOD1 ALS, ALS-FTD, and non-tau FTD. (See",
"      <a class=\"local\" href=\"#H109187262\">",
"       'Abnormalities in RNA metabolism'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Immunoreactive inclusions to FUS in spinal motor neurons have been detected in both sporadic and familial ALS, with the exception of those associated with SOD1 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/67\">",
"       67",
"      </a>",
"      ]. The same inclusions were also immunoreactive with antibodies to TDP-43 and ubiquitin. Earlier studies had not detected FUS-positive immunoreactive inclusions in patients with ALS except for those who had FUS mutations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of amyotrophic lateral sclerosis (ALS) is unknown. A number of potential mechanisms have been proposed including SOD1-mediated toxicity, excitotoxicity, cytoskeletal derangements, mitochondrial dysfunction, viral infections, apoptosis, growth factor abnormalities, inflammatory responses, RNA processing, and others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     SOD1-mediated toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superoxide dismutase type 1 (SOD1) is a metalloenzyme that catalyzes the conversion of toxic superoxide radicals to oxygen (O2) and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    (H2O2). The discovery that mutations in the SOD1 gene are associated with some cases of familial ALS suggested that free radical toxicity may play a role in the process of neuronal cell death or apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, SOD1 mutations have been found in 0.7 to 4 percent of patients with \"sporadic\" ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Familial ALS'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Gain-of-function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damaging accumulation of superoxide could result if SOD1 mutations impaired its antioxidant function. However, several lines of evidence from cell culture and transgenic mutant SOD1 mouse models of ALS have disproved the loss-of-function hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. As an example, SOD1-knockout mice do not develop motor neuron disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is more likely that SOD1 mutations cause disease by a toxic gain-of-function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/73\">",
"     73",
"    </a>",
"    ]. SOD1 has pro-oxidant as well as anti-oxidant activity, and mutated SOD1 could lead to oxidative injury by an increase in pro-oxidant pathways, including generation of hydroxyl radicals and nitration of tyrosine. In support of the toxic gain-of-function hypothesis, there is evidence that mutant SOD1 directly stimulates NADPH oxidase (Nox) in transgenic mice and in human cell lines, and thereby causes overproduction of reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has also been hypothesized that oxidation leads to post-translational modifications of wild-type SOD1, causing it to misfold and thereby gain toxic properties similar to mutant SOD1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/76\">",
"     76",
"    </a>",
"    ]. This mechanism could then be the cause of the majority of cases of classic ALS, which lack SOD1 mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Protein misfolding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another hypothesis is that mutant SOD1 induces protein aggregates that are potentially toxic to motor neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, accumulation of disulfide cross-linked aggregates of mutant SOD1 may be a secondary manifestation of end-stage disease rather than a primary event in the pathogenesis of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/79\">",
"     79",
"    </a>",
"    ]. This hypothesis is supported by a study in transgenic mice, which found that a number of pathologic abnormalities (eg, Golgi apparatus degradation, endplate denervation, reactive astrogliosis) occurred before the levels of aggregated forms of mutant SOD1 increased [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/79\">",
"     79",
"    </a>",
"    ]. The latter was observed only in the final stages of the disease.",
"   </p>",
"   <p>",
"    Nevertheless, very low levels of SOD1 aggregates may be sufficient to mediate toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/79\">",
"     79",
"    </a>",
"    ]. Another possibility is that other forms of mutant SOD1 may be pathologic at early stages of disease. The initial step in the SOD protein assembly pathway is folding of the protein into a homodimeric apo state, and this apo-SOD1 protein is typically associated with severe instability in mutant SOD1 proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The conformational instability of ALS-linked SOD1 mutants may be related to reductional cleavage of the disulfide bond that normally links two cysteine subunits (C57-C146), resulting in an increased propensity of the protein to unfold or misfold and aggregate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/81\">",
"     81",
"    </a>",
"    ]. More unstable and therefore short-lived mutants unfold and become prone to aggregation. In mice, unfolded or misfolded disulfide-reduced SOD1 mutants showed higher steady-state levels in the spinal cord and brain than in peripheral organs, suggesting inefficient recognition and degradation in the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study that analyzed mutant SOD1 from 29 patients with 22 different mutations, lower levels (ie, greater instability) of mutant SOD1 were associated with shorter disease survival time [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/82\">",
"     82",
"    </a>",
"    ]. Thus, patients with less stable mutant SOD1 who accumulate less mutant protein have a more rapid disease course. However, levels of mutant SOD1 were not associated with age at disease onset.",
"   </p>",
"   <p>",
"    These results suggest that the misfolded unstable forms of SOD1 contribute to toxicity and disease progression but not directly to onset, implying different mechanisms of disease onset and progression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/83\">",
"     83",
"    </a>",
"    ]. Supporting this viewpoint is experimental evidence that suppressing mutant SOD1 synthesis selectively in motor neurons delays onset of disease in mice expressing mutant SOD1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28870207\">",
"    <span class=\"h3\">",
"     Individual cell types influence disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutant SOD1 expression in non-neuronal cells may also be involved in the pathogenesis of ALS. Supporting evidence comes from studies in mutant SOD1 mice showing that cell types besides motor neurons play a role in disease onset and progression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/85-89\">",
"     85-89",
"    </a>",
"    ]. In chimeric ALS mice, simple expression of the mutant SOD1 in",
"    <span class=\"nowrap\">",
"     neurons/motor",
"    </span>",
"    neurons was not sufficient to lead to neuronal death; there had to be concomitant expression in glia. Wild-type motor neurons appeared to undergo degeneration when surrounded by mutant SOD1 astroglia. Conversely, wild-type non-neuronal cells surrounding motor neurons expressing mutant SOD1 extended the survival of such motor neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/85\">",
"     85",
"    </a>",
"    ] and increased disease-free life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/90\">",
"     90",
"    </a>",
"    ]. Other reports demonstrated that the reduction of mutant SOD1 selectively from astrocytes in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/89\">",
"     89",
"    </a>",
"    ] or in microglia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/91\">",
"     91",
"    </a>",
"    ] resulted in a slowing of disease progression, but had no effects on disease onset. (See",
"    <a class=\"local\" href=\"#H2160745\">",
"     'Inflammatory responses'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These observations extend beyond the central nervous system, where evidence from a transgenic mouse model overexpressing the human SOD1 G93A mutation suggests that oxidative stress is present in skeletal muscle prior to motor neuron dropout and onset of symptomatic disease, as denoted by compensatory antioxidant enzyme upregulation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/92\">",
"     92",
"    </a>",
"    ]. Skeletal muscle oxidative stress may adversely influence motor neuron survival via direct contact of motor neuron terminals with skeletal muscle and retrograde transport from skeletal muscle to motor neurons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2160745\">",
"    <span class=\"h2\">",
"     Inflammatory responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have shown that inflammatory processes are involved in ALS disease progression and neuronal death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/91,93-100\">",
"     91,93-100",
"    </a>",
"    ]. These inflammatory responses include activation of microglia and astrocytes as well as infiltration of natural killer cells, peripheral T cells, and monocytes into the central nervous system (CNS). Many of these reports have focused on microglia, which are immune-modulating cells of the CNS. Once activated, microglia elaborate a host of factors, including nitric oxide, oxygen radicals, cytokines, glutamate, and others that may play roles in part of the cascade leading to motor neuron cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/101\">",
"     101",
"    </a>",
"    ]. Several lines of evidence suggest that microglial activation is triggered by mutant SOD1 and contributes to neurodegeneration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microglial activation was found to be a prominent part of the spinal cord pathology in several studies employing transgenic mutant SOD1 mice [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/101\">",
"       101",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mutant SOD1 appears to increase the production of damaging reactive oxygen species by activated microglia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/74\">",
"       74",
"      </a>",
"      ], thereby accelerating motor neuron injury [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/75\">",
"       75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In spinal cord cultures, mutant SOD1 induced activation of microglia, increasing their release of proinflammatory cytokines and free radicals, leading to secondary motor neuron injury [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/102\">",
"       102",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Misfolded mutant SOD1 activates caspase-1 and the proinflammatory cytokine interleukin-1&beta; in microglia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/103\">",
"       103",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Excitotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excitotoxicity hypothesis postulates that excessive levels of the excitatory neurotransmitter glutamate may initiate a cascade resulting in cellular death of motor neurons in ALS. Excessive activation of glutamate receptors may lead to increased entry of calcium into cells. In turn, intracellular calcium may trigger a cascade of events that causes neuronal cell death via lipid peroxidation, nucleic acid damage, and mitochondrial disruption.",
"   </p>",
"   <p>",
"    The role of excitotoxicity in ALS remains unsettled. In support of the excitotoxicity hypothesis is the finding of elevated glutamate levels in the cerebrospinal fluid of patients with sporadic ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. In addition, defects in glutamate transport that may contribute to excessive extracellular glutamate have been noted in 80 percent of patients with sporadic ALS and in the transgenic mutant SOD1 mouse model of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/106-108\">",
"     106-108",
"    </a>",
"    ]. These defects involve transmembrane glutamate transporters located on neurons and particularly on glial cells that are normally responsible for rapid inactivation of glutamate after its release.",
"   </p>",
"   <p>",
"    One hypothesis suggests that non-functional, truncated forms of one glutamate transporter subtype (EAAT2), the primary glutamate transporter on astrocytes, may be particularly prominent in ALS tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/106\">",
"     106",
"    </a>",
"    ]. However, some of these truncated forms have also been found in normal tissue. Additionally, it appears that a splice-variant of this protein (EAAT2b) may actually be upregulated in ALS, particularly in neurons. These findings suggest that there may be a potential compensatory effect to increase other glutamate transporters in the presence of elevated extracellular glutamate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glutamate receptor dysfunction is another potential mechanism for excitotoxicity. A number of postsynaptic glutamate receptors may be involved in this process, including the N-methyl-D-aspartic acid (NMDA) receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor, the kainate receptor, and the G-protein-coupled receptor. As an example, defective editing of messenger RNA that encodes for a subunit of glutamate AMPA receptors has been found in spinal motor neurons of patients with ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/110\">",
"     110",
"    </a>",
"    ]. This glutamate editing defect has been linked to increased permeability to calcium ions through this AMPA receptor subtype and may result in downstream effects leading to neuronal death.",
"   </p>",
"   <p>",
"    Deficiency in glutamate dehydrogenase activity may also lead to excitotoxicity; this has been demonstrated in some but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perhaps some of the best evidence suggesting that glutamate excitotoxicity may have a role in ALS disease progression is the demonstration that the antiglutaminergic drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    improves survival in patients with the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23240?source=see_link&amp;anchor=H2#H2\">",
"     \"Disease modifying treatment of amyotrophic lateral sclerosis\", section on 'Riluzole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, other drugs affecting glutamate neurotransmission have not been successful in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109187262\">",
"    <span class=\"h2\">",
"     Abnormalities in RNA metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The co-localization of TDP-43 and FUS in non-SOD1 ALS inclusions suggests that these",
"    <span class=\"nowrap\">",
"     DNA/RNA",
"    </span>",
"    binding proteins are involved in the pathogenesis of non-SOD1 forms of ALS. In-vitro studies indicate that mutant TDP-43 polypeptides have greater stability than those of the wild-type TDP-43 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/112\">",
"     112",
"    </a>",
"    ], rather than lesser stability as occurs with mutant SOD1. In addition, mutant TDP-43 shows enhanced binding to normal",
"    <span class=\"nowrap\">",
"     FUS/TLS.",
"    </span>",
"    These findings imply that mutant TDP-43 may disrupt normal",
"    <span class=\"nowrap\">",
"     FUS/TLS",
"    </span>",
"    function and suggest a convergence of their pathogenic mechanisms in ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Intracellular inclusions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Mounting evidence supports the hypothesis that altered RNA metabolism plays a role in neurodegeneration related to mutations in TDP-43 and FUS proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. The TDP-43 and FUS proteins are normally found predominantly in the nucleus, where they are involved in RNA processing. Wild-type TDP-43 and FUS are transported to the nucleus by nuclear import receptors. However, mutant forms of TDP-43 with C-terminal truncations lack the nuclear transport signal, causing mislocalization of the protein to the cytoplasm. Similarly, ALS-associated FUS mutations impair nuclear transport and result in mislocalization to the cytoplasm. In sporadic ALS, aging may cause an accelerated increase in nuclear permeability and leakiness, with wild-type TDP-43 and FUS accumulating in the cytoplasm. The accumulation of TDP-43 and FUS in the cytoplasm is thought to lead to neurodegeneration, either by disturbing the RNA quality control regulation or by the formation of stress granules (",
"    <a class=\"graphic graphic_figure graphicRef64595 \" href=\"UTD.htm?43/47/44791\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ALS susceptibility factor ataxin 2 (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Genetic susceptibility in sporadic ALS'",
"    </a>",
"    above), a constituent of stress granules and a putative RNA binding protein, may interact in the common pathologic pathway formed by TDP-43 and FUS (",
"    <a class=\"graphic graphic_figure graphicRef77362 \" href=\"UTD.htm?12/9/12437\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/113\">",
"     113",
"    </a>",
"    ]. In contrast, the pathologic process related to SOD1 mutations (see",
"    <a class=\"local\" href=\"#H12\">",
"     'SOD1-mediated toxicity'",
"    </a>",
"    above) may be independent of the TDP-43 and FUS pathologic cascade.",
"   </p>",
"   <p>",
"    TDP-43 accumulation and inclusion formation (ie, TDP-proteinopathy) is observed in most sporadic ALS cases as well as most sporadic cases of frontotemporal dementia and cases of overlapping ALS with dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/115\">",
"     115",
"    </a>",
"    ]. In addition, TDP-43 neuronal cytoplasmic inclusions are found in familial ALS related to mutations in a number of genes, which include the TARDBP gene that encodes for TDP-43, the VAPB gene, the CHMP2B gene, and to a lesser extent the C9ORF72 gene. However, in postmortem tissue from patients with C9ORF72 gene mutations, TDP-43 positive inclusions appear to be less common than TDP-43 negative inclusions containing ubiquitin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/116\">",
"     116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link\">",
"     \"Familial amyotrophic lateral sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cytoskeletal derangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intracellular neurofilament inclusions found within degenerating motor neurons may be involved in the pathogenesis of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. Neurofilaments are a type of intermediate filament expressed at high levels by motor neurons, and they are formed by the assembly of light, medium, and heavy subunits. They normally function as structural elements that perform vital roles in maintaining cell shape, axonal caliber, and axonal transport.",
"   </p>",
"   <p>",
"    Deranged neurofilaments could disrupt axonal transport and cause axonal strangulation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/119\">",
"     119",
"    </a>",
"    ]. Mutations in the neurofilament heavy subunit gene have been found in sporadic and familial forms of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. Reduction in the light subunit mRNA levels was detected in spinal motor neurons of ALS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/122\">",
"     122",
"    </a>",
"    ]. Overexpression or deletion of neurofilament subunits in transgenic mice resulted in motor neuron degeneration and axonal swellings with neurofilaments similar to those seen in ALS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/119,123\">",
"     119,123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peripherin, an intermediate filament, is associated with neurofilaments in neuronal inclusions of patients with sporadic ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/124\">",
"     124",
"    </a>",
"    ]. Overexpression of peripherin in transgenic mice is associated with degeneration of motor axons, and inflammatory cytokines may increase peripherin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/125\">",
"     125",
"    </a>",
"    ], suggesting a link between inflammation and ALS through interaction with peripherin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/19\">",
"     19",
"    </a>",
"    ]. Whether the neurofilament inclusions seen in ALS are a cause or effect of neuronal degeneration is not yet settled [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibition of axonal transport may be a cause of motor neuron degeneration. Defects in the dynein-dynactin complex, a molecular motor responsible for axonal transport along microtubules, have been linked with motor degeneration in the mouse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/127\">",
"     127",
"    </a>",
"    ], and a mutant dynactin has been linked with a progressive LMN disorder in a human family [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/128,129\">",
"     128,129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mitochondrial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial dysfunction occurs early in the transgenic mutant SOD1 mouse model, preceding other evidence of motor neuron damage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/130\">",
"     130",
"    </a>",
"    ]. Data suggest that a selective recruitment of mutant SOD1 to spinal cord mitochondria, when compared with less affected tissues, may explain the abundant pathology in the spinal cord of the transgenic mutant SOD1 mouse [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/131\">",
"     131",
"    </a>",
"    ]. Human biochemical and morphologic studies demonstrate consistent mitochondrial abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. These abnormalities may be the result of oxidative stress and, in turn, may potentiate it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poliovirus, enteroviruses, and exogenous or inherited endogenous retroviruses, have been proposed to be causative agents of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/134-138\">",
"     134-138",
"    </a>",
"    ]. However, exhaustive studies have never confirmed a clear etiologic relationship. Human immunodeficiency virus (HIV) infection and Lyme disease rarely cause an ALS-like syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/139,140\">",
"     139,140",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=see_link&amp;anchor=H15#H15\">",
"     \"Polio and infectious diseases of the anterior horn\", section on 'Viruses and amyotrophic lateral sclerosis syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apoptosis or programmed cell death cascades have been implicated in several studies of the SOD1 mouse. These reports have shown a number of the hallmarks of apoptosis including DNA fragmentation, caspase activation, and altered expression of the antiapoptotic protein Bcl-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/77,141\">",
"     77,141",
"    </a>",
"    ]. Some evidence suggests that apoptosis may be a late pathway for motor neuron degeneration in ALS, but its importance in ALS has been controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/142,143\">",
"     142,143",
"    </a>",
"    ]. However, one study found that genetic deletion of the mitochondrial apoptotic pathway in a mouse model of ALS halted neuronal loss and prevented axonal degeneration, symptom onset, and paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/144\">",
"     144",
"    </a>",
"    ]. In addition, survival was extended. These findings suggest that inhibition of apoptosis is a possible therapeutic strategy for ALS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth factors such as brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and insulin-like growth factor (IGF-1) have been studied previously both for their possible role in the etiology in ALS and for their therapeutic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/145-148\">",
"     145-148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discovery that patients who have a specific haplotype for vascular endothelial growth factor (VEGF) may be more susceptible to ALS has increased enthusiasm for the possible role of growth factors in this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/149,150\">",
"     149,150",
"    </a>",
"    ]. Additional attention to this growth factor is based on the finding that a cross between the VEGF knockout mouse and the transgenic mutant SOD1 mouse resulted in earlier death and more severe loss of motor neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/149\">",
"     149",
"    </a>",
"    ]. Treatment of these animal models with VEGF in a number of different paradigms has resulted in significant improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/57/23450/abstract/151,152\">",
"     151,152",
"    </a>",
"    ], thus establishing VEGF as a potential candidate in ALS pathogenesis and targeting it for use in therapeutic studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28871029\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amyotrophic lateral sclerosis (ALS) is classified as either sporadic or familial. Sporadic forms account for about 90 percent of ALS cases, while familial forms make up the remaining 10 percent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=see_link\">",
"       \"Familial amyotrophic lateral sclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Incidence rates for ALS in Europe and North America range between 1.5 and 2.7 per",
"      <span class=\"nowrap\">",
"       100,000/year,",
"      </span>",
"      while prevalence rates range between 2.7 and 7.4 per 100,000. The male to female ratio is about 1.3 to 1.5 for sporadic ALS, although the ratio becomes closer to unity in the age group over 70 years. The incidence of ALS increases with each decade, especially after age 40 years. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence and prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Established risk factors for ALS are age and family history. Accumulating evidence suggests that cigarette smoking is also a risk factor for ALS. There are weak or conflicting data for other putative nongenetic risk factors, a list that includes military service, agricultural work, factory work, heavy manual labor, exposure to welding or soldering, exposure to heavy metal, work in the plastics industry, repetitive muscle use, athleticism, playing professional soccer, trauma, and electrical shock. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of genes that act as Mendelian genes in familial ALS (SOD1, TARDBP, C9ORF72, ANG, FUS, OPTN, and SETX) may also be low-penetrance susceptibility factors in sporadic ALS. Although not described in familial ALS, expansions in the ATXN2 gene and duplications of the SMN1 gene are associated with an increased risk of ALS. Current evidence suggests that there are additional low-risk genetic susceptibility loci for sporadic ALS awaiting confirmation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      discovery. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Genetic susceptibility in sporadic ALS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High prevalence clusters of ALS are found in three regions of the western Pacific including Guam, West New Guinea, and the Kii Peninsula in Japan. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Geographic clusters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ALS is characterized by motor neuron degeneration and death with gliosis replacing lost neurons. Cortical motor cells (pyramidal and Betz cells) disappear, leading to retrograde axonal loss and gliosis in the corticospinal tract. The spinal cord becomes atrophic. The ventral roots become thin, and there is a loss of large myelinated fibers in motor nerves. The affected muscles show denervation atrophy with evidence of reinnervation such as fiber type grouping. Intracellular inclusions in degenerating neurons and glia are frequent neuropathological findings of ALS. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of ALS is not established. A number of mechanisms have been proposed, including SOD1-mediated toxicity, excitotoxicity, abnormalities in RNA metabolism, cytoskeletal derangements, mitochondrial dysfunction, viral infections, apoptosis, growth factor abnormalities, inflammatory responses, and others. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/1\">",
"      Rowland LP. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol 2001; 58:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/2\">",
"      Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci 2001; 191:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/3\">",
"      Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010; 81:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/4\">",
"      Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology 2007; 68:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/5\">",
"      Chancellor AM, Warlow CP. Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J Neurol Neurosurg Psychiatry 1992; 55:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/6\">",
"      Noonan CW, White MC, Thurman D, Wong LY. Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998. Neurology 2005; 64:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/7\">",
"      Murphy M, Quinn S, Young J, et al. Increasing incidence of ALS in Canterbury, New Zealand: a 22-year study. Neurology 2008; 71:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/8\">",
"      Chi&ograve; A, Magnani C, Schiffer D. Gompertzian analysis of amyotrophic lateral sclerosis mortality in Italy, 1957-1987; application to birth cohorts. Neuroepidemiology 1995; 14:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/9\">",
"      Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology 2009; 73:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/10\">",
"      Gallo V, Bueno-De-Mesquita HB, Vermeulen R, et al. Smoking and risk for amyotrophic lateral sclerosis: analysis of the EPIC cohort. Ann Neurol 2009; 65:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/11\">",
"      Sutedja NA, Veldink JH, Fischer K, et al. Lifetime occupation, education, smoking, and risk of ALS. Neurology 2007; 69:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/12\">",
"      Armon C, Kurland LT, Daube JR, O'Brien PC. Epidemiologic correlates of sporadic amyotrophic lateral sclerosis. Neurology 1991; 41:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/13\">",
"      Felmus MT, Patten BM, Swanke L. Antecedent events in amyotrophic lateral sclerosis. Neurology 1976; 26:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/14\">",
"      Longstreth WT, McGuire V, Koepsell TD, et al. Risk of amyotrophic lateral sclerosis and history of physical activity: a population-based case-control study. Arch Neurol 1998; 55:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/15\">",
"      Scarmeas N, Shih T, Stern Y, et al. Premorbid weight, body mass, and varsity athletics in ALS. Neurology 2002; 59:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/16\">",
"      Chi&ograve; A, Benzi G, Dossena M, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005; 128:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/17\">",
"      Veldink JH, Kalmijn S, Groeneveld GJ, et al. Physical activity and the association with sporadic ALS. Neurology 2005; 64:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/18\">",
"      Perl DP, Gajdusek DC, Garruto RM, et al. Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science 1982; 217:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/19\">",
"      Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/20\">",
"      Mitchell JD. Heavy metals and trace elements in amyotrophic lateral sclerosis. Neurol Clin 1987; 5:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/21\">",
"      Kamel F, Umbach DM, Munsat TL, et al. Lead exposure and amyotrophic lateral sclerosis. Epidemiology 2002; 13:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/22\">",
"      Gresham LS, Molgaard CA, Golbeck AL, Smith R. Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case-control study. Neuroepidemiology 1986; 5:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/23\">",
"      Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology 2003; 61:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/24\">",
"      Horner RD, Kamins KG, Feussner JR, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 2003; 61:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/25\">",
"      Weisskopf MG, O'Reilly EJ, McCullough ML, et al. Prospective study of military service and mortality from ALS. Neurology 2005; 64:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/26\">",
"      Rose MR. Gulf War service is an uncertain trigger for ALS. Neurology 2003; 61:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/27\">",
"      Gellera C, Castellotti B, Riggio MC, et al. Superoxide dismutase gene mutations in Italian patients with familial and sporadic amyotrophic lateral sclerosis: identification of three novel missense mutations. Neuromuscul Disord 2001; 11:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/28\">",
"      Greenway MJ, Andersen PM, Russ C, et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 2006; 38:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/29\">",
"      Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/30\">",
"      Talbot K. Another gene for ALS: mutations in sporadic cases and the rare variant hypothesis. Neurology 2009; 73:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/31\">",
"      Belzil VV, Valdmanis PN, Dion PA, et al. Mutations in FUS cause FALS and SALS in French and French Canadian populations. Neurology 2009; 73:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/32\">",
"      B&auml;umer D, Hilton D, Paine SM, et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 2010; 75:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/33\">",
"      Lattante S, Conte A, Zollino M, et al. Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease. Neurology 2012; 79:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/34\">",
"      Zhao ZH, Chen WZ, Wu ZY, et al. A novel mutation in the senataxin gene identified in a Chinese patient with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009; 10:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/35\">",
"      Fecto F, Yan J, Vemula SP, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2011; 68:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/36\">",
"      Rubino E, Rainero I, Chi&ograve; A, et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 2012; 79:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/37\">",
"      Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010; 466:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/38\">",
"      Van Damme P, Veldink JH, van Blitterswijk M, et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 2011; 76:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/39\">",
"      Lee T, Li YR, Chesi A, et al. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology 2011; 76:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/40\">",
"      Sorar&ugrave; G, Clementi M, Forzan M, et al. ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion. Neurology 2011; 76:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/41\">",
"      Fischbeck KH, Pulst SM. Amyotrophic lateral sclerosis and spinocerebellar ataxia 2. Neurology 2011; 76:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/42\">",
"      Darras BT. More can be less: SMN1 gene duplications are associated with sporadic ALS. Neurology 2012; 78:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/43\">",
"      Blauw HM, Barnes CP, van Vught PW, et al. SMN1 gene duplications are associated with sporadic ALS. Neurology 2012; 78:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/44\">",
"      Corcia P, Mayeux-Portas V, Khoris J, et al. Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Ann Neurol 2002; 51:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/45\">",
"      Veldink JH, Kalmijn S, Van der Hout AH, et al. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Neurology 2005; 65:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/46\">",
"      Corcia P, Camu W, Halimi JM, et al. SMN1 gene, but not SMN2, is a risk factor for sporadic ALS. Neurology 2006; 67:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/47\">",
"      Dunckley T, Huentelman MJ, Craig DW, et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med 2007; 357:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/48\">",
"      van Es MA, Van Vught PW, Blauw HM, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol 2007; 6:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/49\">",
"      Traynor BJ, Singleton A. Genome-wide association studies and ALS: are we there yet? Lancet Neurol 2007; 6:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/50\">",
"      Siddique T. What is missing in ALS. Lancet Neurol 2008; 7:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/51\">",
"      Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82:623.",
"     </a>",
"    </li>",
"    <li>",
"     Zimmerman, HM. Monthly report to the medical officer in command. United States Navy Medical Research Unit No. 2. June 1945.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/53\">",
"      KURLAND LT, MULDER DW. Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution, with special reference to the Mariana Islands, including clinical and pathologic observations. Neurology 1954; 4:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/54\">",
"      Spencer PS, Nunn PB, Hugon J, et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 1987; 237:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/55\">",
"      Cox PA, Sacks OW. Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology 2002; 58:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/56\">",
"      Steele JC, McGeer PL. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 2008; 70:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/57\">",
"      Parvizi J, Anderson SW, Martin CO, et al. Pathological laughter and crying: a link to the cerebellum. Brain 2001; 124:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/58\">",
"      Bradley WG, Good P, Rasool CG, Adelman LS. Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis. Ann Neurol 1983; 14:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/59\">",
"      Arisato T, Okubo R, Arata H, et al. Clinical and pathological studies of familial amyotrophic lateral sclerosis (FALS) with SOD1 H46R mutation in large Japanese families. Acta Neuropathol 2003; 106:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/60\">",
"      Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/61\">",
"      Tan CF, Eguchi H, Tagawa A, et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol 2007; 113:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/62\">",
"      Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/63\">",
"      Neumann M, Kwong LK, Sampathu DM, et al. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. Arch Neurol 2007; 64:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/64\">",
"      Geser F, Martinez-Lage M, Robinson J, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009; 66:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/65\">",
"      Okamoto Y, Ihara M, Urushitani M, et al. An autopsy case of SOD1-related ALS with TDP-43 positive inclusions. Neurology 2011; 77:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/66\">",
"      Sumi H, Kato S, Mochimaru Y, et al. Nuclear TAR DNA binding protein 43 expression in spinal cord neurons correlates with the clinical course in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2009; 68:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/67\">",
"      Deng HX, Zhai H, Bigio EH, et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol 2010; 67:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/68\">",
"      Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/69\">",
"      Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 2006; 6:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/70\">",
"      Chi&ograve; A, Traynor BJ, Lombardo F, et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology 2008; 70:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/71\">",
"      Gurney ME. Transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med 1994; 331:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/72\">",
"      Reaume AG, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996; 13:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/73\">",
"      Gurney ME. Transgenic animal models of familial amyotrophic lateral sclerosis. J Neurol 1997; 244 Suppl 2:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/74\">",
"      Harraz MM, Marden JJ, Zhou W, et al. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest 2008; 118:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/75\">",
"      Boill&eacute;e S, Cleveland DW. Revisiting oxidative damage in ALS: microglia, Nox, and mutant SOD1. J Clin Invest 2008; 118:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/76\">",
"      Kabashi E, Valdmanis PN, Dion P, Rouleau GA. Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis? Ann Neurol 2007; 62:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/77\">",
"      Durham HD, Roy J, Dong L, Figlewicz DA. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol 1997; 56:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/78\">",
"      Cleveland DW, Liu J. Oxidation versus aggregation - how do SOD1 mutants cause ALS? Nat Med 2000; 6:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/79\">",
"      Karch CM, Prudencio M, Winkler DD, et al. Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. Proc Natl Acad Sci U S A 2009; 106:7774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/80\">",
"      Lindberg MJ, Tibell L, Oliveberg M. Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state. Proc Natl Acad Sci U S A 2002; 99:16607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/81\">",
"      Jonsson PA, Graffmo KS, Andersen PM, et al. Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain 2006; 129:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/82\">",
"      Sato T, Nakanishi T, Yamamoto Y, et al. Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology 2005; 65:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/83\">",
"      Yamanaka K, Cleveland DW. Determinants of rapid disease progression in ALS. Neurology 2005; 65:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/84\">",
"      Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005; 11:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/85\">",
"      Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003; 302:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/86\">",
"      Dupuis L, di Scala F, Rene F, et al. Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. FASEB J 2003; 17:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/87\">",
"      Dobrowolny G, Giacinti C, Pelosi L, et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 2005; 168:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/88\">",
"      Borchelt DR. Amyotrophic lateral sclerosis--are microglia killing motor neurons? N Engl J Med 2006; 355:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/89\">",
"      Yamanaka K, Chun SJ, Boillee S, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008; 11:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/90\">",
"      Yamanaka K, Boillee S, Roberts EA, et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci U S A 2008; 105:7594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/91\">",
"      Boill&eacute;e S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006; 312:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/92\">",
"      Mahoney DJ, Kaczor JJ, Bourgeois J, et al. Oxidative stress and antioxidant enzyme upregulation in SOD1-G93A mouse skeletal muscle. Muscle Nerve 2006; 33:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/93\">",
"      Troost D, Van den Oord JJ, Vianney de Jong JM. Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 1990; 16:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/94\">",
"      Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992; 140:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/95\">",
"      Neusch C, B&auml;hr M, Schneider-Gold C. Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease? Muscle Nerve 2007; 35:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/96\">",
"      Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 2011; 10:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/97\">",
"      Beers DR, Henkel JS, Zhao W, et al. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A 2008; 105:15558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/98\">",
"      Lincecum JM, Vieira FG, Wang MZ, et al. From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet 2010; 42:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/99\">",
"      Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007; 10:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/100\">",
"      Butovsky O, Siddiqui S, Gabriely G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 2012; 122:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/101\">",
"      Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998; 23:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/102\">",
"      Zhao W, Beers DR, Henkel JS, et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 2010; 58:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/103\">",
"      Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci U S A 2010; 107:13046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/104\">",
"      Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/105\">",
"      Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995; 4:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/106\">",
"      Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/107\">",
"      Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/108\">",
"      Dunlop J, Beal McIlvain H, She Y, Howland DS. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 2003; 23:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/109\">",
"      Maragakis NJ, Dykes-Hoberg M, Rothstein JD. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol 2004; 55:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/110\">",
"      Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004; 427:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/111\">",
"      Pioro EP, Majors AW, Mitsumoto H, et al. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology 1999; 53:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/112\">",
"      Ling SC, Albuquerque CP, Han JS, et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A 2010; 107:13318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/113\">",
"      Ito D, Suzuki N. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS. Neurology 2011; 77:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/114\">",
"      Buratti E. TDP-43 and FUS in ALS/FTLD: will common pathways fit all? Neurology 2011; 77:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/115\">",
"      Ince PG, Highley JR, Kirby J, et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol 2011; 122:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/116\">",
"      Gijselinck I, Van Langenhove T, van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 2012; 11:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/117\">",
"      Morrison BM, Morrison JH, Gordon JW. Superoxide dismutase and neurofilament transgenic models of amyotrophic lateral sclerosis. J Exp Zool 1998; 282:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/118\">",
"      Lin H, Schlaepfer WW. Role of neurofilament aggregation in motor neuron disease. Ann Neurol 2006; 60:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/119\">",
"      Collard JF, C&ocirc;t&eacute; F, Julien JP. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 1995; 375:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/120\">",
"      Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/121\">",
"      Al-Chalabi A, Andersen PM, Nilsson P, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/122\">",
"      Wong NK, He BP, Strong MJ. Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). J Neuropathol Exp Neurol 2000; 59:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/123\">",
"      C&ocirc;t&eacute; F, Collard JF, Julien JP. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993; 73:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/124\">",
"      Corbo M, Hays AP. Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. J Neuropathol Exp Neurol 1992; 51:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/125\">",
"      Sterneck E, Kaplan DR, Johnson PF. Interleukin-6 induces expression of peripherin and cooperates with Trk receptor signaling to promote neuronal differentiation in PC12 cells. J Neurochem 1996; 67:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/126\">",
"      Julien JP, Beaulieu JM. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci 2000; 180:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/127\">",
"      LaMonte BH, Wallace KE, Holloway BA, et al. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002; 34:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/128\">",
"      Puls I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003; 33:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/129\">",
"      Puls I, Oh SJ, Sumner CJ, et al. Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol 2005; 57:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/130\">",
"      Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998; 18:3241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/131\">",
"      Liu J, Lillo C, Jonsson PA, et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 2004; 43:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/132\">",
"      Cassarino DS, Bennett JP Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Brain Res Rev 1999; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/133\">",
"      Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005; 58:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/134\">",
"      Swanson NR, Fox SA, Mastaglia FL. Search for persistent infection with poliovirus or other enteroviruses in amyotrophic lateral sclerosis-motor neurone disease. Neuromuscul Disord 1995; 5:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/135\">",
"      Nix WA, Berger MM, Oberste MS, et al. Failure to detect enterovirus in the spinal cord of ALS patients using a sensitive RT-PCR method. Neurology 2004; 62:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/136\">",
"      Jubelt B, Lipton HL. ALS: persistent scientists do not find persisting enteroviruses. Neurology 2004; 62:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/137\">",
"      Steele AJ, Al-Chalabi A, Ferrante K, et al. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology 2005; 64:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/138\">",
"      McCormick AL, Brown RH Jr, Cudkowicz ME, et al. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology 2008; 70:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/139\">",
"      Halperin JJ. Nervous system Lyme disease. J Neurol Sci 1998; 153:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/140\">",
"      Moulignier A, Moulonguet A, Pialoux G, Rozenbaum W. Reversible ALS-like disorder in HIV infection. Neurology 2001; 57:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/141\">",
"      Spooren WP, Hengerer B. DNA laddering and caspase 3-like activity in the spinal cord of a mouse model of familial amyotrophic lateral sclerosis. Cell Mol Biol (Noisy-le-grand) 2000; 46:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/142\">",
"      Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999; 58:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/143\">",
"      He BP, Strong MJ. Motor neuronal death in sporadic amyotrophic lateral sclerosis (ALS) is not apoptotic. A comparative study of ALS and chronic aluminium chloride neurotoxicity in New Zealand white rabbits. Neuropathol Appl Neurobiol 2000; 26:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/144\">",
"      Reyes NA, Fisher JK, Austgen K, et al. Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J Clin Invest 2010; 120:3673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/145\">",
"      A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 1999; 52:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/146\">",
"      Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol 1996; 39:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/147\">",
"      Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997; 49:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/148\">",
"      Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998; 51:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/149\">",
"      Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/150\">",
"      Terry PD, Kamel F, Umbach DM, et al. VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS). J Neurogenet 2004; 18:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/151\">",
"      Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/57/23450/abstract/152\">",
"      Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005; 8:85.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5156 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23450=[""].join("\n");
var outline_f22_57_23450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28871029\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence and prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic susceptibility in sporadic ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Familial ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Geographic clusters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intracellular inclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SOD1-mediated toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Gain-of-function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Protein misfolding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28870207\">",
"      - Individual cell types influence disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2160745\">",
"      Inflammatory responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Excitotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109187262\">",
"      Abnormalities in RNA metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cytoskeletal derangements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mitochondrial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Apoptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28871029\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5156\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5156|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/47/44791\" title=\"figure 1\">",
"      Hypothetical pathology TDP-43 and FUS proteinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/9/12437\" title=\"figure 2\">",
"      Possible pathologic cascade ALS and FTLD-linked molecules",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23240?source=related_link\">",
"      Disease modifying treatment of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16138?source=related_link\">",
"      Familial amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=related_link\">",
"      Polio and infectious diseases of the anterior horn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=related_link\">",
"      Spinal muscular atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_57_23451="Amyloidosis early mortality score";
var content_f22_57_23451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Early mortality score for amyloidosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Prognostic model",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Risk groups",
"       </td>",
"       <td class=\"subtitle1\">",
"        One-year mortality rate",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Early mortality score",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        Low risk",
"       </td>",
"       <td>",
"        Cardiac troponin &le;0.01 microg/L, NT-proBNP &le;4200 ng/L, and serum uric acid &le;8.0 mg/dL",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low-intermediate risk",
"       </td>",
"       <td>",
"        Any one factor high",
"       </td>",
"       <td>",
"        37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High-intermediate risk",
"       </td>",
"       <td>",
"        Any two factors high",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High risk",
"       </td>",
"       <td>",
"        Cardiac troponin T level &gt;0.01 microg/L, NT-proBNP &gt;4200 ng/L, and serum uric acid &gt;8.0 mg/dL",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <ol>",
"      <li>",
"       Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011; 86:12.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23451=[""].join("\n");
var outline_f22_57_23451=null;
var title_f22_57_23452="FPIES oral food challenge";
var content_f22_57_23452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F87566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F87566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Food protein-induced enterocolitis syndrome (FPIES) oral food challenge",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Protocol",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Basic requirements: Clinician supervision, secure intravenous (IV) access, immediate availability of fluid resuscitation",
"         </li>",
"         <li>",
"          Baseline vital signs and complete blood count with differential to determine the baseline peripheral blood neutrophil count",
"         </li>",
"         <li>",
"          Administration of food protein 0.06 to 0.6 g/kg body weight in three equal doses over 45 minutes generally not to exceed total 3 g protein or 10 g of total food (100 mL of liquid) for an initial feeding. A lower dose is used in patients with a history of severe reactions.",
"         </li>",
"         <li>",
"          If no reaction occurs within two to three hours of administration of the final dose, feed the patient an age appropriate serving of the food followed by four hours of observation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criteria for a positive challenge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 \">",
"        <strong>",
"         Symptoms",
"        </strong>",
"        <ul>",
"         <li>",
"          Emesis (onset one to three hours)",
"         </li>",
"         <li>",
"          Lethargy (onset one to three hours)",
"         </li>",
"         <li>",
"          Diarrhea (onset two to ten hours, mean five hours)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        <strong>",
"         Laboratory",
"        </strong>",
"        <ul>",
"         <li>",
"          Elevated neutrophil count (&gt;3500 cells/mL, peaks at six hours). This is evaluated by obtaining a complete blood count with differential approximately six hours after the start of a challenge if the patient becomes symptomatic.",
"         </li>",
"         <li>",
"          Fecal leukocytes, red blood cells, and/or eosinophils. This study is only performed if the patient develops diarrhea.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment for a positive challenge*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          First line therapy: Fluid resuscitation with 20 mL/kg IV boluses of normal saline (0.9 percent sodium chloride)",
"         </li>",
"         <li>",
"          Therapy for hypotension/shock: Intramuscular (IM) epinephrine 0.01 mg/kg per dose using 1 mg/mL solution (also labeled 1:1000); maximum single dose 0.5 mL (0.5 mg); may repeat after 5 to 15 minutes if needed",
"         </li>",
"         <li>",
"          Additional therapy for severe reactions: Glucocorticoids (eg, methylprednisolone 1 mg/kg IV, maximum 80 mg)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Treatment is initiated in patients with severe, repetitive emesis; significant tachycardia; hypotension; and/or dusky appearance.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23452=[""].join("\n");
var outline_f22_57_23452=null;
var title_f22_57_23453="Rx of Raynauds Phenomenon";
var content_f22_57_23453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment options for the Raynaud phenomenon",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Simple measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonpharmacologic",
"       </td>",
"       <td>",
"        <p>",
"         Hand warmers",
"        </p>",
"        <p>",
"         Protective clothing",
"        </p>",
"       </td>",
"       <td>",
"        Universally helpful; also useful to minimize cold exposure and ambient temperature changes in work environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Pharmacologic",
"       </td>",
"       <td>",
"        Evening primrose oil",
"       </td>",
"       <td>",
"        Has been shown effective in controlled clinical trial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fish oil capsules",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Topical vasodilators",
"       </td>",
"       <td>",
"        NTG patches",
"       </td>",
"       <td>",
"        Shown effective in short term use but often causes headaches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Oral vasodilators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium channel blockers",
"       </td>",
"       <td>",
"        <p>",
"         Nifedipine (extended release)",
"        </p>",
"        <p>",
"         Nicardipine",
"        </p>",
"        <p>",
"         Felodipine",
"        </p>",
"        <p>",
"         Amlodipine",
"        </p>",
"       </td>",
"       <td>",
"        Responses often idiosyncratic; therefore best to try several drugs in rotation to find most effective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ACE inhibitors",
"       </td>",
"       <td>",
"        <p>",
"         Captopril",
"        </p>",
"        <p>",
"         Enalapril",
"        </p>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; color: #000000; font-size: 11pt;\">",
"         Class benefit not shown in controlled trial of quinapril.&nbsp;ACEi mandatory in hypertensive renal crisis",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serotonin antagonist",
"       </td>",
"       <td>",
"        Ketanserin",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; color: #000000; font-size: 11pt;\">",
"         Only available on named-patient basis but beneficial in clinical trials",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serotonin reuptake inhibitors",
"       </td>",
"       <td>",
"        Fluoxetine",
"       </td>",
"       <td>",
"        Possible beneficial effects on Raynaud in addition to anti-depressant activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endothelin antagonist",
"       </td>",
"       <td>",
"        Bosentan",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; color: #000000; font-size: 11pt;\">",
"         Beneficial in reducing the incidence of digital ulceration in SSc. Effect on Raynaud unproven",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; color: #000000; font-size: 11pt;\">",
"         Selective PDE5 inhibitors",
"        </span>",
"       </td>",
"       <td>",
"        <p>",
"         <span style=\"line-height: 115%; font-family: calibri,sans-serif; color: #000000; font-size: 11pt;\">",
"          Sildenafil",
"         </span>",
"        </p>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; color: #000000; font-size: 11pt;\">",
"         Tadalafil",
"        </span>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; color: #000000; font-size: 11pt;\">",
"         Reports of benefit in reducing Raynaud attach severity and frequency and possible improvement in digital ulceration",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Parental vasodilators",
"       </td>",
"       <td>",
"        <p>",
"         Carboprostacyclin (iloprost)",
"        </p>",
"        <p>",
"         Prostaglandin E1",
"        </p>",
"       </td>",
"       <td>",
"        Effective and reasonably tolerated. Given for severe frequent attacks of RP, digital ulceration or gangrene and prior to digital surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Antibiotics",
"       </td>",
"       <td>",
"        Flucloxacillin",
"       </td>",
"       <td>",
"        Important in secondary erythromycin infection in RP. Prolonged oral administration may be necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Surgical procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lumbar sympathectomy",
"       </td>",
"       <td>",
"        Chemical or operative",
"       </td>",
"       <td>",
"        For severe RP of lower limbs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Digital sympathectomy (radical microarteriolysis)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Useful treatment for isolated ischemia of one or two digits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Debridement",
"        </p>",
"        <p>",
"         Amputation",
"        </p>",
"       </td>",
"       <td>",
"        Surgical or autoamputation",
"       </td>",
"       <td>",
"        Surgery should be conservative to allow maximum possibility of spontaneous healing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23453=[""].join("\n");
var outline_f22_57_23453=null;
var title_f22_57_23454="Pharmacologic echo outcome";
var content_f22_57_23454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pharmacologic echocardiography and outcome among patients with single vessel disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 509px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panel: Among 754 patients with single vessel coronary artery disease, the four year rate of survival free of infarction or cardiac death in those treated medically was significantly greater when a dobutamine or dipyridamole echocardiogram was negative compared to a positive study (94 versus 87 percent). Bottom panel: In contrast, in patients undergoing coronary revascularization, a positive or negative pharmacologic echocardiogram, obtained prior to revascularization, was not significantly predictive of outcome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Cortigiani, L, Picano, E, Landi, P, et al, J Am Coll Cardiol 1998; 32:69.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23454=[""].join("\n");
var outline_f22_57_23454=null;
var title_f22_57_23455="Confirmation of the diagnosis of anaphylaxis";
var content_f22_57_23455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F76947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F76947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Confirmation of the diagnosis of anaphylaxis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 547px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Common entities in the differential diagnosis include: acute hives, acute asthma, anxiety/panic attack, syncope/faint, and choking on/aspiration of a foreign body. There are many less common entities, including histamine syndromes, restaurant syndromes, flush syndromes, and other forms of shock.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_57_23455=[""].join("\n");
var outline_f22_57_23455=null;
